Author Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 15:13:23 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Nov 2009  VOL 151 ISS 19
FILE LAST UPDATED: 4 Nov 2009  (20091104/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L21
L1              STR
```




```
G1 C,N
```

```
Structure attributes must be viewed using STN Express query preparation.
L5          545 SEA FILE=REGISTRY SSS FUL L1
L7              STR
```




```
G1 C,N
```

```
Structure attributes must be viewed using STN Express query preparation.
L9          462 SEA FILE=REGISTRY SUB=L5 SSS FUL L7
L11           7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L9
L12          30 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GOBLE S?/AU
L13       18995 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  YANG L?/AU
L14        7601 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  ZHOU C?/AU
L15          22 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  KOTHANDARAMAN S?/AU
L16          18 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GUIADEEN D?/AU
L17          53 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  BUTORA G?/AU
L18           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PASTEMAK A?/AU
L19         794 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  MILLS S?/AU
L20       27313 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR
                L15 OR L16 OR L17 OR L18 OR L19)
L21           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L20 AND L11


=> FILE WPIX
FILE 'WPIX' ENTERED AT 15:13:29 ON 05 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED:          2 NOV 2009   <20091102/UP>
MOST RECENT UPDATE:           200970      <200970/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    mid-June 2009.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/
```

```
EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<
'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L25
L7              STR
```




```
G1 C,N



Structure attributes must be viewed using STN Express query preparation.
L12          30 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GOBLE S?/AU
L13       18995 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  YANG L?/AU
L14        7601 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  ZHOU C?/AU
L15          22 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  KOTHANDARAMAN S?/AU
L16          18 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GUIADEEN D?/AU
L17          53 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  BUTORA G?/AU
L18           2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PASTEMAK A?/AU
L19         794 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  MILLS S?/AU
L20       27313 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR
                L15 OR L16 OR L17 OR L18 OR L19)
L23         131 SEA FILE=WPIX SSS FUL L7
L24           3 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L23/DCR
L25           3 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L20 AND L24


=> DUP REM L21 L25
FILE 'HCAPLUS' ENTERED AT 15:13:39 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 15:13:39 ON 05 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS
PROCESSING COMPLETED FOR L21
PROCESSING COMPLETED FOR L25
L30             6 DUP REM L21 L25 (3 DUPLICATES REMOVED)
                  ANSWERS '1-6' FROM FILE HCAPLUS

=> D IBIB ED ABS HITSTR L30 1-6

L30  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2005:1328611  HCAPLUS  Full-text
DOCUMENT NUMBER:          144:69736
TITLE:                    Preparation of tetrahydropyranyl
                          cyclopentylcarboxamide modulators of chemokine
```

receptor activity
INVENTOR(S): Yang, Lihu; Mills, Sander G.; Jiao, Richard
PATENT ASSIGNEE(S): Merck & Co., Inc, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120505	A2	20051222	WO 2005-US13754	20050422
WO 2005120505	A3	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005251678	A1	20051222	AU 2005-251678	20050422
CA 2564499	A1	20051222	CA 2005-2564499	20050422
EP 1742915	A2	20070117	EP 2005-784477	20050422
CN 1972913	A	20070530	CN 2005-80013054	20050422
JP 2007534756	T	20071129	JP 2007-510819	20050422
IN 2006DN06022	A	20070831	IN 2006-DN6022	20061016
US 20080021061	A1	20080124	US 2006-587288	20061023
US 7557124	B2	20090707		
PRIORITY APPLN. INFO.:			US 2004-565380P	P 20040426
			WO 2005-US13754	W 20050422

OTHER SOURCE(S): CASREACT 144:69736; MARPAT 144:69736
ED Entered STN: 22 Dec 2005
GI



I



II

AB Title compds. I [Y = O, S, SO2, (un)substituted amino, etc.; Z = C or N; R1 = sulfonylalkyl, alkylamino, sulfonylamino, etc.; R2 = H, OH, halo, alkyl, etc.;

R3 = H, (fluoro)alkyl, hydroxy, etc.; ; R4 = H, (fluoro)alkyl, Ph, etc.; R5 = alkyl, alkoxy, pyridyl, etc.; R6 = H, alkyl, Ph, etc.; R7 = H or (un)substituted alkyl; R8 = H, OH, F, etc., or R7R8 = cyclyl; R9 = H, OH, (un)substituted alkyl, alkyloxy, etc., or R8R9 = cyclyl; R10 = H, F, cycloalkyloxy, (un)substituted alkyloxy, (fluoro)alkyl, or R8R10 = cyclyl; R15, R16 = independently H, OH, (un)substituted alkyl, etc.; n = 0-2] and their pharmaceutically acceptable salts were prepared and disclosed as modulators of chemokine receptor activity (no data). Thus, II was prepared by condensation of tetrahydro-4H-pyran-4-one with the corresponding amino cyclopentyl precursor (preparation given). These compds. are useful as modulators of the chemokine receptor for the prevention or treatment of certain inflammatory and immunoregulatory disorders, such as rheumatoid arthritis (no data).

IT 693246-51-4P 693246-68-3P 693273-51-7P
693273-52-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyranyl cyclopentylcarboxamide modulators of chemokine receptor activity)

RN 693246-51-4 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-68-3 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-51-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-52-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 693246-45-6P 693246-48-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydropyranyl cyclopentylcarboxamide modulators of chemokine receptor activity)
RN 693246-45-6 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(methylthio)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-48-9 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(methylsulfonyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:673016 HCAPLUS Full-text
DOCUMENT NUMBER: 143:172854
TITLE: Alkylamino, arylamino, and sulfonamido cyclopentane amide modulators of chemokine receptor activity
INVENTOR(S): Goble, Stephen D.; Yang, Lihu; Zhou, Changyou; Kothandaraman, Shankaran; Guiadeen, Deodialsingh; Butora, Gabor; Pasternak, Alexander; Mills, Sander G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005067502	A2	20050728	WO 2004-US43777	20041229
WO 2005067502	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004313486	A1	20050728	AU 2004-313486	20041229
CA 2551869	A1	20050728	CA 2004-2551869	20041229
EP 1701724	A2	20060920	EP 2004-815779	20041229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1897941	A	20070117	CN 2004-80038562	20041229
JP 2007519633	T	20070719	JP 2006-547521	20041229
IN 2006DN03272	A	20070420	IN 2006-DN3272	20060607
US 20070117797	A1	20070524	US 2006-585232	20060630
PRIORITY APPLN. INFO.:			US 2004-533892P P	20040102
			WO 2004-US43777 W	20041229

OTHER SOURCE(S): CASREACT 143:172854; MARPAT 143:172854
ED Entered STN: 29 Jul 2005
GI



I



II

AB Title compds. I [Z = N, C, where no more than two Z are N; R1 = OH, CN, (un)substituted alkyl/alkyl, Ph, etc.; when Z attached to R2 is N, R2 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; when Z attached to R3 is N, R3 = absent or O; and when Z attached to R3 is C, R3 = H, OH, halo, (un)substituted alkyl, etc.;when Z attached to R4 is N, R4 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; R5 = (un)substituted alkyl, alkylcarbonyl, Ph, etc.; when Z attached

to R6 is N, R4 = absent or O; and when Z attached to R6 is C, R6 = H, (un)substituted alkyl, alkoxy; R7 = H, (un)substituted alkyl, Ph, heterocyclyl; R8 = (un)substituted alkyl, Ph, pyridyl, etc.; R10, R16 = independently (:O), H, Ph, (un)substituted alkyl; R15 = H, alkyl; or R2 and R15 join together to form a carbocycle or heterocycle; X = (CH2)n; n = 0-1; and their pharmaceutically acceptable salts and individual diastereomers] were prepared as chemokine receptor, particularly CCR2, modulators. For example, II was prepared in 3 steps starting from 3-trifluoromethyl-5,6,7,8-tetrahydro-1,6-naphthyridine (preparation given). I bound to CCR2 receptor in a binding and chemotaxis assay with an IC50 of less than about 1 μM. The invention is directed to the pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, rheumatoid arthritis, etc. (no data).

IT 860796-11-8P 860796-13-0P 860796-15-2P
860796-17-4P 860796-19-6P 860796-20-9P
860796-21-0P 860796-22-1P 860796-23-2P
860796-24-3P 860796-25-4P 860796-26-5P
860796-27-6P 860796-28-7P 860796-75-4P
860796-78-7P 860796-79-8P 860796-80-1P
860796-81-2P 860796-82-3P 860796-83-4P
860796-84-5P 860796-85-6P 860796-86-7P
860796-87-8P 860796-88-9P 860796-89-0P
860796-90-3P 860796-91-4P 860796-92-5P
860796-93-6P 860796-94-7P 860796-95-8P
860796-96-9P 860796-97-0P 860796-98-1P
860796-99-2P 860797-00-8P 860797-01-9P
860797-02-0P 860797-03-1P 860797-05-3P
860797-06-4P 860797-07-5P 860797-08-6P
860797-09-7P 860797-10-0P 860797-11-1P
860797-12-2P 860797-13-3P 860797-30-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)

RN 860796-11-8 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-fluorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-13-0 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(phenylmethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-15-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-chlorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-17-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[[4-(methylthio)phenyl]methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-19-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[[4-(methylsulfonyl)phenyl]methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-20-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-21-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-22-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2-chlorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-23-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3-chlorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-24-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2-methoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-25-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3-methoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-26-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-methoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-27-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(2-pyridinylmethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-28-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(3-pyridinylmethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-75-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-chlorophenyl)methyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)



RN 860796-78-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(methylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-79-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[1-(3,5-dimethoxyphenyl)ethyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-80-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2,4-dimethoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-81-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3,4-dimethoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-82-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[1-(3,4-dimethoxyphenyl)ethyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-83-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[1-(4-methoxyphenyl)ethyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-84-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[ethyl(phenylmethyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-85-6 HCAPLUS
CN Cyclopentanecarboxamide, 3-[bis(phenylmethyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-86-7 HCAPLUS
CN Benzenesulfinic acid, 4-[[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-87-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1-methylethyl)(phenylmethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-88-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2,4,6-trimethoxyphenyl)methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-89-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3,5-dimethoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-90-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2,3-dimethoxyphenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-91-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3-iodophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-92-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3-fluorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-93-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3,4-difluorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-94-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[[4-(dimethylamino)phenyl]methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-95-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1-naphthalenylmethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-96-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[1-(1-naphthalenyl)ethyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-97-0 HCAPLUS
CN Benzeneacetic acid, α-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-98-1 HCAPLUS
CN Benzeneacetic acid, α-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, methyl ester, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860796-99-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-00-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2-bromophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-01-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2-fluorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-02-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-bromophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-03-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-05-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(3,4,5-trimethoxyphenyl)methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-06-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-hydroxyethyl)(phenylmethyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-07-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2-nitrophenyl)methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-08-6 HCAPLUS
CN Cyclopentanecarboxamide, 3-[[[4-(aminosulfonyl)phenyl]methyl]amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-09-7 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(1,3-benzodioxol-5-ylmethyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-10-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(2,4-dichlorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-11-1 HCAPLUS
CN Cyclopentanecarboxamide, 3-[([1,1'-biphenyl]-2-ylmethyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-12-2 HCAPLUS
CN Cyclopentanecarboxamide, 3-[([1,1'-biphenyl]-3-ylmethyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-13-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-30-4 HCAPLUS
CN Alanine, N-[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 693245-66-8P 693245-67-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)
RN 693245-66-8 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-67-9 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 693245-63-5P 860797-34-8P 860797-35-9P
860797-36-0P 860797-37-1P 860797-38-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)

RN 693245-63-5 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-34-8 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-35-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(2-nitrophenyl)sulfonyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-36-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl[(2-nitrophenyl)sulfonyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-37-1 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-38-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1029820-47-0 1029820-58-3 1029822-79-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)
RN 1029820-47-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(ethylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1029820-58-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1-methylethyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1029822-79-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-hydroxyethyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 860797-45-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)
RN 860797-45-1 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:412748 HCAPLUS Full-text
DOCUMENT NUMBER: 140:423677
TITLE: Preparation of 3-(tetrahydropyranylamino)cyclopentanecarboxylic acid N-benzylamide derivatives and related compounds as modulators of chemokine receptor activity
INVENTOR(S): Butora, Gabor; Mills, Sander G.; Pasternak, Alexander; Shankaran, Kothandaraman; Yang, Lihu; Zhou, Changyou; Goble, Stephen D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041161	A2	20040521	WO 2003-US33972	20031024
WO 2004041161	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502174	A1	20040521	CA 2003-2502174	20031024
AU 2003286701	A1	20040607	AU 2003-286701	20031024
AU 2003286701	B2	20081218		
EP 1558243	A2	20050803	EP 2003-777911	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514003	T	20060427	JP 2004-550126	20031024
US 20060116421	A1	20060601	US 2005-533326	20050502
US 7390803	B2	20080624		
PRIORITY APPLN. INFO.:			US 2002-422451P	P 20021030
			WO 2003-US33972	W 20031024

OTHER SOURCE(S): MARPAT 140:423677
ED Entered STN: 21 May 2004
GI



I



II

AB The title compds. (I) [wherein: X = O, NR20, S, SO, SO2, CR21R22, NSO2R20, NCOR20, NCO2R20, CR21CO2R20, CR21OCOR20, CO, OC(Me)2O (where R20 = H, C1-6 alkyl, benzyl, Ph, C3-6 cycloalkyl, etc.; R21, R22 = H, HO, C1-6 alkyl, C1-6 alkoxy, benzyl, Ph, C3-6 cycloalkyl, etc.); R1 = C1-6 alkyl, C1-6 alkoxy-C0-6 alkyl, C1-6 alkyl-S(O)0-2-C0-6-alkyl, N-(un)substituted C1-6 alkylaminosulfonyl-C0-6alkyl, -(C0-6 alkyl)(C3-7 cycloalkyl)(C0-6 alkyl), HO, CO2R20, heterocyclyl, cyano, NR20R26, NR26SO2R20, NR26COR21, OCOR20, Ph (where R26 = H, C1-6 alkyl, benzyl, Ph, etc.); R2, R4, R6 = H, C1-6 alkyl, CF3, CF3O, Cl, Br, Ph; R3 = H, HO, halo, C1-6 alkyl, C1-6 alkoxy, , NR20R21, NR20CO2R21, NR20CONR20OR21, NR20SO2NR20R21, NR20SO2R21, heterocyclyl, cyano, CONR20R21, CO2R20, NO2, SR20, SOR20, SO2R20, SO2NR20R21: R5 = C1-6 alkyl substituted with 1-6 F and optionally substituted with HO, C1-6 alkoxy or CO-C1-6 alkyl each

substituted with 1-6 fluoro, C1-6 alkylthio, pyridyl, F, Cl, Br, Ph; R7 = H, C1-6 alkyl, CF3; R8, R9, R10 = H, (un)substituted C1-6 alkyl; or R7 and R8 or R8 and R9 may be joined together to form a ring; R11 = H, C1-6 alkyl, CF3; R27, R28 = oxo, H, Ph, (un)substituted C1-6 alkyl; R29, R30, R31 = H, Me, HO, CF3, MeO, CF3O; or R29 and R9 are connected by a C1-3alkyl bridge; m, n = 0-2; the dashed line = a single or a double bond] and pharmaceutically acceptable salts thereof and individual diastereomers thereof are prepared These compds. are useful as modulators of the chemokine receptor CCR-2 for (a) treating, ameliorating or controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease or (b) treating, ameliorating or controlling rheumatoid arthritis (no data). Thus, reductive amination of N-[3,5-bis(trifluoromethyl)benzyl]-3-oxo-1- isopropylcyclopentane-1-carboxamide with 4-aminotetrahydro-4H-pyran hydrochloride using triacetoxyborohydride in the presence of diisopropylethylamine in CH2Cl2 at room temperature overnight gave 46% N-[3,5-bis(trifluoromethyl)benzyl]-3-(tetrahydro-4H-pyran-4-ylamino)-oxo-1- isopropylcyclopentane-1-carboxamide (II).

IT 1055897-33-0
RL: PRPH (Prophetic)
(Preparation of 3-(tetrahydropyranylamino)cyclopentanecarboxylic acid N-benzylamide derivatives and related compounds as modulators of chemokine receptor activity)

RN 1055897-33-0 HCAPLUS

CN Cyclopentanecarboxamide, 1-(1-methylethyl)-N-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 693246-26-3P 693246-66-1P 693246-67-2P
693246-96-7P 693246-97-8P 693247-21-1P
693247-23-3P 693247-25-5P 693247-27-7P
693247-88-0P 693248-78-1P 693248-79-2P
693248-81-6P 693248-91-8P 693248-92-9P
693248-94-1P 693248-95-2P 693249-67-1P
693249-68-2P 693249-69-3P 693249-70-6P
693283-48-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzyl(tetrahydropyranylamino)cyclopentanecarboxamide derivs. and related compds. as modulators of chemokine receptor CCR-2 for treating inflammatory or immunoregulatory disorders or diseases or rheumatoid arthritis)

RN 693246-26-3 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-66-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-67-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-96-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-hydroxy-1,1-dimethylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 693246-97-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-hydroxy-1,1-dimethylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 693247-21-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-23-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-25-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-27-7 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-4-C-(trifluoromethyl)-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-88-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-78-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(3S,4S)-tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-79-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(3R,4R)-tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-81-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl(9-syn)-3-oxabicyclo[3.3.1]non-9-ylamino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-91-8 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 693248-92-9 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 693248-94-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclobutyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 693248-95-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclobutyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 693249-67-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2R,4R)-tetrahydro-2-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-68-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2R,4S)-tetrahydro-2-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-69-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2S,4S)-tetrahydro-2-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-70-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(2S,4R)-tetrahydro-2-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-48-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl(9-anti)-3-oxabicyclo[3.3.1]non-9-ylamino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 693245-93-1P 693245-94-2P 693246-15-0P
693246-37-6P 693246-87-6P 693248-45-2P
693248-46-3P 693249-08-0P 693249-12-6P
693249-23-9P 693249-24-0P 693249-25-1P
693249-30-8P 693249-31-9P 693249-32-0P
693249-50-2P 693250-29-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-benzyl(tetrahydropyranylamino)cyclopentanecarboxamide derivs. and related compds. as modulators of chemokine receptor CCR-2 for treating inflammatory or immunoregulatory disorders or diseases or rheumatoid arthritis)

RN 693245-93-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693245-94-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-15-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-N-[[3-iodo-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-37-6 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethyl)-5-(trimethylstannyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-87-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-4-hydroxy-, phenylmethyl ester (CA INDEX NAME)



RN 693248-45-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyano-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-46-3 HCAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-08-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R,3S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[methyl(tetrahydro-2H-

pyran-4-yl)amino]cyclopentyl]-, phenylmethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-12-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-23-9 HCAPLUS
CN Carbamic acid, [4-[1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693249-24-0 HCAPLUS
CN Carbamic acid, [4-[1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693249-25-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-30-8 HCAPLUS
CN Carbamic acid, [4-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693249-31-9 HCAPLUS
CN Carbamic acid, [4-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 693249-32-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-50-2 HCAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 693250-29-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX

NAME)

Relative stereochemistry.



IT 693245-95-3P 693245-96-4P 693245-97-5P
693245-98-6P 693245-99-7P 693246-02-5P
693246-03-6P 693246-04-7P 693246-05-8P
693246-06-9P 693246-07-0P 693246-08-1P
693246-09-2P 693246-10-5P 693246-11-6P
693246-12-7P 693246-17-2P 693246-18-3P
693246-19-4P 693246-20-7P 693246-21-8P
693246-22-9P 693246-23-0P 693246-24-1P
693246-25-2P 693246-27-4P 693246-28-5P
693246-29-6P 693246-30-9P 693246-31-0P
693246-32-1P 693246-33-2P 693246-36-5P
693246-38-7P 693246-39-8P 693246-40-1P
693246-43-4P 693246-47-8P 693246-49-0P
693246-50-3P 693246-51-4P 693246-64-9P
693246-65-0P 693246-68-3P 693246-69-4P
693246-70-7P 693246-71-8P 693246-73-0P
693246-74-1P 693246-75-2P 693246-76-3P
693246-77-4P 693246-78-5P 693246-79-6P
693246-80-9P 693246-81-0P 693246-82-1P
693246-83-2P 693246-84-3P 693246-88-7P
693246-89-8P 693246-90-1P 693246-94-5P
693246-95-6P 693246-98-9P 693247-18-6P
693247-19-7P 693247-22-2P 693247-24-4P
693247-26-6P 693247-28-8P 693247-29-9P
693247-30-2P 693247-31-3P 693247-32-4P
693247-33-5P 693247-34-6P 693247-35-7P
693247-36-8P 693247-37-9P 693247-38-0P
693247-39-1P 693247-40-4P 693247-42-6P
693247-43-7P 693247-44-8P 693247-45-9P
693247-46-0P 693247-47-1P 693247-48-2P
693247-49-3P 693247-50-6P 693247-51-7P
693247-52-8P 693247-53-9P 693247-54-0P
693247-55-1P 693247-56-2P 693247-57-3P
693247-58-4P 693247-59-5P 693247-60-8P
693247-61-9P 693247-62-0P 693247-63-1P
693247-64-2P 693247-65-3P 693247-66-4P
693247-68-6P 693247-69-7P 693247-70-0P
693247-71-1P 693247-72-2P 693247-73-3P
693247-74-4P 693247-75-5P 693247-76-6P
693247-77-7P 693247-78-8P 693247-79-9P
693247-80-2P 693247-82-4P 693247-83-5P
693247-84-6P 693247-85-7P 693247-86-8P
693247-87-9P 693247-89-1P 693247-90-4P
693247-91-5P 693247-92-6P 693247-93-7P
693247-94-8P 693247-95-9P 693247-96-0P

693247-97-1P 693247-98-2P 693247-99-3P
693248-00-9P 693248-01-0P 693248-05-4P
693248-06-5P 693248-10-1P 693248-11-2P
693248-42-9P 693248-47-4P 693248-49-6P
693248-52-1P 693248-56-5P 693248-58-7P
693248-59-8P 693248-61-2P 693248-62-3P
693248-65-6P 693248-68-9P 693248-72-5P
693248-75-8P 693248-76-9P 693248-77-0P
693248-80-5P 693248-85-0P 693248-86-1P
693248-87-2P 693248-88-3P 693248-89-4P
693248-90-7P 693248-93-0P 693249-01-3P
693249-02-4P 693249-03-5P 693249-04-6P
693249-05-7P 693249-06-8P 693249-07-9P
693249-09-1P 693249-10-4P 693249-11-5P
693249-13-7P 693249-14-8P 693249-17-1P
693249-21-7P 693249-27-3P 693249-33-1P
693249-34-2P 693249-35-3P 693249-36-4P
693249-41-1P 693249-43-3P 693249-44-4P
693249-45-5P 693249-49-9P 693249-51-3P
693249-52-4P 693249-56-8P 693249-57-9P
693249-58-0P 693249-59-1P 693249-63-7P
693249-65-9P 693249-66-0P 693249-71-7P
693249-75-1P 693249-76-2P 693249-81-9P
693249-82-0P 693249-87-5P 693249-88-6P
693249-89-7P 693249-90-0P 693249-91-1P
693249-92-2P 693249-93-3P 693249-94-4P
693249-95-5P 693249-96-6P 693249-97-7P
693249-98-8P 693249-99-9P 693250-00-9P
693250-01-0P 693250-02-1P 693250-03-2P
693250-04-3P 693250-05-4P 693250-06-5P
693250-10-1P 693250-11-2P 693250-12-3P
693250-13-4P 693250-14-5P 693250-16-7P
693250-17-8P 693250-18-9P 693250-19-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-benzyl(tetrahydropyranylamino)cyclopentanecarboxamide derivs. and related compds. as modulators of chemokine receptor CCR-2 for treating inflammatory or immunoregulatory disorders or diseases or rheumatoid arthritis)

RN 693245-95-3 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693245-96-4 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-

methylethyl)-3-[propyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693245-97-5 HCAPLUS
CN Glycine, N-[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-(tetrahydro-2H-pyran-4-yl)-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693245-98-6 HCAPLUS
CN 2H-Pyran-4-aminium, N-[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]tetrahydro-N,N-dimethyl-, iodide (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693245-99-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-

methylethyl)-3-[methyloxido(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel-
(CA INDEX NAME)

Relative stereochemistry.



RN 693246-02-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-(3-fluorophenyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-03-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(3-fluorophenyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-04-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(3-methoxyphenyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-05-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(3-methoxyphenyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-06-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(2-thienyl)- (CA INDEX NAME)



RN 693246-07-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(2-thienyl)- (CA INDEX NAME)



RN 693246-08-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(3-thienyl)- (CA INDEX NAME)



RN 693246-09-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(3-thienyl)- (CA INDEX NAME)



RN 693246-10-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-phenyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-11-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-phenyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-12-7 HCAPLUS
CN Cyclopentanecarboxamide, 3-[acetyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 693246-17-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-chloro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-18-3 HCAPLUS
CN Cyclopentanecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-19-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-20-7 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-21-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693246-22-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-dichlorophenyl)methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-23-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-24-1 HCAPLUS
CN Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-, 4-(3-chlorobenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-25-2 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-27-4 HCAPLUS
CN Cyclopentanecarboxamide, 3-(cyclohexylamino)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-28-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-29-6 HCAPLUS
CN Cyclopentanecarboxylic acid, 3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-30-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1-methyl-4-piperidinyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-31-0 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(1-acetyl-4-piperidinyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-32-1 HCAPLUS
CN Cyclopentanecarboxylic acid, 3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-33-2 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-36-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-38-7 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-39-8 HCAPLUS
CN Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-40-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-43-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-cyclopropyl-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-47-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylthio)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-49-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-50-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1-methylethyl)thio]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-51-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-64-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-65-0 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-68-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-69-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-70-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-

yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-71-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-73-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-74-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-75-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[ethyl[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-76-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-77-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(2-methylcyclohexyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-78-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-79-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-80-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-4-methyl-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-81-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-4-methyl-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-82-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-4-methyl-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-83-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[methyl(tetrahydro-4-methyl-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-84-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-88-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(4-hydroxy-4-piperidinyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX

NAME)



RN 693246-89-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(tetrahydro-4-hydroxy-2H-pyran-4-yl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-90-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(dicyclopropylhydroxymethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-94-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-hydroxy-1,1-dimethylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-95-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-hydroxy-1,1-dimethylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-98-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1,1-dimethylpropyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693247-18-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxyethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-19-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxyethyl)-3-[[1-(hydroxymethyl)cyclopentyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-22-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-24-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-26-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-28-8 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-4-C-(trifluoromethyl)-2,3-dideoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-29-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-propyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-30-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-propyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-31-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,3-dimethyl-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693247-32-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,3-dimethyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-33-5 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-34-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-35-7 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-36-8 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro-, ethyl ester, hydrochloride

(1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-37-9 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-38-0 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-39-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-

methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-40-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-42-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-43-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-44-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-45-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-46-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-oxepanylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-47-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-oxepanylamino)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-48-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-furanyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-49-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-furanyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-50-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(tetrahydro-3-furanyl)methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-51-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(tetrahydro-3-furanyl)methyl]amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-52-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-thienyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-53-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-thienyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-54-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxetanylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-55-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxetanylamino)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-56-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-57-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-58-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methylcyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-59-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methylcyclohexyl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693247-60-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cycloheptylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-61-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cycloheptylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-62-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-63-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-64-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclobutylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-65-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclobutylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-66-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(cyclobutylmethyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-68-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(cyclobutylmethyl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-69-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-70-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-71-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-1-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-72-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-1-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-73-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-74-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-75-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-76-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-77-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-78-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-79-9 HCAPLUS
CN Hexonic acid, 2,6-anhydro-4-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-3,4,5-trideoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-80-2 HCAPLUS
CN Hexonic acid, 2,6-anhydro-4-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-3,4,5-trideoxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-82-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-83-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-84-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-piperidinylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-85-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-piperidinylamino)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-86-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-87-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-89-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-90-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-91-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-92-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-93-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-94-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-95-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-96-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-97-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-hydroxy-1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-98-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-99-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693248-00-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-01-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)methylamino]-1-(1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693248-05-4 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-06-5 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693248-10-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(1H-tetrazol-1-yl)-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-11-2 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(1H-tetrazol-1-yl)-5-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693248-42-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-47-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(1H-1,2,4-triazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-49-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(2-methyl-2H-tetrazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-52-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[1-(methylsulfonyl)-3-piperidinyl]amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-56-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1α,5α,6β)-3-oxabicyclo[3.1.0]hex-6-ylamino]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 693248-58-7 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-59-8 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-4-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-61-2 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-62-3 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-4-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-65-6 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-4-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-68-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-72-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-75-8 HCAPLUS
CN Carbamic acid, [(1R,3R)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-76-9 HCAPLUS
CN Cyclopentanecarboxamide, 1-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-77-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-80-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(9-anti)-3-oxabicyclo[3.3.1]non-9-ylamino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-85-0 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclohexyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-86-1 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclohexyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-87-2 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclohexyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693248-88-3 HCAPLUS

CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693248-89-4 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-90-7 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-93-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxycyclobutyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-01-3 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-02-4 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693249-03-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclohexyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-04-6 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-

yl)amino]- (CA INDEX NAME)



RN 693249-05-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclobutyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-06-8 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-, phenylmethyl ester (CA INDEX NAME)



RN 693249-07-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R,3S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-, phenylmethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-09-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(4-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-10-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-acetyl-4-piperidinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-11-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[1-(methylsulfonyl)-4-piperidinyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-13-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(phenylmethyl)- (CA INDEX NAME)



RN 693249-14-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-17-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-21-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-propyl-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-27-3 HCAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-33-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-34-2 HCAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-35-3 HCAPLUS

CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)- (CA INDEX NAME)



RN 693249-36-4 HCAPLUS

CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-4-thiazolyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)- (CA INDEX NAME)



RN 693249-41-1 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methyl-4-thiazolyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693249-43-3 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methyl-4-thiazolyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-44-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methyl-4-thiazolyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-45-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(4-thiazolyl)- (CA INDEX NAME)



RN 693249-49-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(1H-1,2,4-triazol-1-yl)-2H-pyran-4-yl]amino]-, hydrochloride (1:2), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 693249-51-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(1H-tetrazol-1-yl)-2H-pyran-4-yl]amino]-, hydrochloride (1:2), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 693249-52-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(1H-tetrazol-1-yl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-56-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2R)-2-cyanocyclopropyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-57-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-cyanocyclopropyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-58-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-cyanocyclopropyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-59-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2R)-2-cyanocyclopropyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-63-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(3-exo)-8-oxabicyclo[3.2.1]oct-3-ylamino]- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-65-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(phenylmethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-66-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(phenylmethyl)-2H-pyran-4-yl]amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-71-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)methylamino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-75-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-76-2 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(4H-1,2,4-triazol-4-yl)-5-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-81-9 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(2H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-82-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(2H-tetrazol-5-yl)-5-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-87-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(3H-1,2,4-triazol-5-yl)-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-88-6 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(3H-1,2,4-triazol-5-yl)-5-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693249-89-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)- (CA INDEX NAME)



RN 693249-90-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 693249-91-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methylethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-92-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(trans-4-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



RN 693249-93-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-94-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-

[[(1R,2R)-2-hydroxycyclohexyl]amino]-1-(1-methylethyl)-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693249-95-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dimethylcyclohexyl)amino]-1-(1-methylethyl)- (CA INDEX NAME)



RN 693249-96-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dimethylcyclohexyl)amino]-1-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 693249-95-5
CMF C26 H36 F6 N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 693249-97-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methylcyclohexyl)amino]-1-(1-methylethyl)- (CA INDEX NAME)



RN 693249-98-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methylcyclohexyl)amino]-1-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 693249-97-7
CMF C25 H34 F6 N2 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 693249-99-9 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,

N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-00-9 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693250-01-0 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-02-1 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,

N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693250-03-2 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-04-3 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1'-hydroxy-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693250-05-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(methylsulfonyl)amino]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693250-06-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-(acetylamino)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-10-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-cyano-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-11-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-cyano-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693250-12-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693250-13-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693250-14-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693250-16-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693250-17-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693250-18-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(4-piperidinyl)- (CA INDEX NAME)



RN 693250-19-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-acetyl-4-piperidinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



IT 693250-20-3P 693250-30-5P 693250-31-6P
693250-32-7P 693273-47-1P 693273-48-2P
693273-49-3P 693273-50-6P 693273-51-7P
693273-52-8P 693273-53-9P 693273-54-0P
693273-55-1P 693273-56-2P 693273-57-3P
693273-58-4P 693273-59-5P 693273-60-8P
693273-61-9P 693273-62-0P 693273-63-1P
693273-64-2P 693273-65-3P 693273-66-4P
693283-50-0P 693283-52-2P 693283-54-4P
693283-56-6P 693283-58-8P 693283-60-2P
693283-63-5P 693283-65-7P 693283-67-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzyl(tetrahydropyranylamino)cyclopentanecarboxamide derivs. and related compds. as modulators of chemokine receptor CCR-2 for treating inflammatory or immunoregulatory disorders or diseases or rheumatoid arthritis)

RN 693250-20-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[1-(methylsulfonyl)-4-piperidinyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693250-30-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-4-methyl-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693250-31-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-hydroxy-1,1-dimethylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693250-32-7 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]cyclopentyl]-, phenylmethyl ester (CA INDEX NAME)



RN 693273-47-1 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-48-2 HCAPLUS
CN Cyclobutanecarboxylic acid, 3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-49-3 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-50-6 HCAPLUS
CN Cyclobutanecarboxylic acid, 3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-51-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-52-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylsulfonyl)-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-53-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,5-dimethyl-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693273-54-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,5-dimethyl-2H-pyran-4-yl)amino]-,

hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693273-55-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-methylcyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-56-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-methylcyclohexyl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693273-57-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-58-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-59-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(octahydro-2H-1-benzopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-60-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1α,5α,6α)-3-oxabicyclo[3.1.0]hex-6-ylamino]-, (1S,3R)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 693273-61-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(6-hydroxy-3-oxabicyclo[3.3.1]non-9-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-62-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(3-oxabicyclo[3.3.1]non-6-en-9-ylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-63-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(methyl-3-oxabicyclo[3.3.1]non-6-en-9-ylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-64-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-5-methyl-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-65-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxabicyclo[3.2.1]oct-8-ylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-66-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxabicyclo[3.2.1]oct-8-ylamino)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-50-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(methyl-3-oxabicyclo[3.3.1]non-9-ylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-52-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(9-syn)-3-oxabicyclo[3.3.1]non-9-ylamino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-54-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693283-56-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693283-58-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693283-60-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-63-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, hydrochloride (1:1), (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693283-65-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(8-oxabicyclo[3.2.1]oct-3-ylamino)-, hydrochloride (1:1), (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693283-67-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxabicyclo[3.1.0]hex-6-ylamino)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 693245-63-5P 693245-64-6P 693245-66-8P
693245-67-9P 693245-74-8P 693245-75-9P
693245-78-2P 693246-13-8P 693246-14-9P
693246-45-6P 693246-46-7P 693246-48-9P
693246-52-5P 693246-53-6P 693246-93-4P
693247-15-3P 693247-17-5P 693248-02-1P
693248-04-3P 693248-48-5P 693248-50-9P
693248-51-0P 693248-57-6P 693248-60-1P
693248-66-7P 693248-67-8P 693248-70-3P
693248-71-4P 693248-73-6P 693248-74-7P
693248-99-6P 693249-00-2P 693249-15-9P
693249-16-0P 693249-19-3P 693249-20-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-benzyl(tetrahydropyranylamino)cyclopentanecarboxamide derivs. and related compds. as modulators of chemokine receptor CCR-2 for treating inflammatory or immunoregulatory disorders or diseases or rheumatoid arthritis)

RN 693245-63-5 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-64-6 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693245-66-8 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-67-9 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-74-8 HCAPLUS
CN Carbamic acid, [(1R,3R)-3-azido-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-75-9 HCAPLUS
CN Carbamic acid, [(1R,3R)-3-amino-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693245-78-2 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-azido-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-13-8 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-(1-hydroxy-1-methylethyl)-3-[[[[3-iodo-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-14-9 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-1-(1-hydroxy-1-methylethyl)-N-[[3-iodo-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-45-6 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(methylthio)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-46-7 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methylthio)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-48-9 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(methylsulfonyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-52-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-N-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-53-6 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-N-(phenylmethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693246-93-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1,1-dimethyl-2-propen-1-yl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693247-15-3 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-

hydroxyethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-17-5 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxyethyl)-, (1S,3R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 693247-16-4
CMF C17 H20 F6 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 693248-02-1 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-04-3 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-48-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-1-(2H-tetrazol-5-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-50-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[(1R,3S)-3-[[[[3,5-

bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-51-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-piperidinylamino)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 693248-57-6 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-, 4-(3-chlorobenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-60-1 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-, 4-(3-chlorobenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-66-7 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-methylcyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-67-8 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-methyl-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-70-3 HCAPLUS
CN Carbamic acid, [(1R)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-ethylcyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-71-4 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-, hydrochloride (1:1), (3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693248-73-6 HCAPLUS
CN Carbamic acid, [(1R,3R)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-74-7 HCAPLUS
CN Carbamic acid, [(1R,3R)-3-amino-1-[[[[3,5-

bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-,
phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-99-6 HCAPLUS
CN [1,1'-Bicyclopentyl]-1-carboxamide,
3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-hydroxy-, (1S,3R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 693249-00-2 HCAPLUS
CN Carbamic acid, [(1S,3R)-1-[[[3,5-
bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-1'-hydroxy[1,1'-
bicyclopentyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-15-9 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[1-[3,5-

bis(trifluoromethyl)phenyl]ethyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-16-0 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693249-19-3 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-propylcyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693249-20-6 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-propyl-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L30 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:300680 HCAPLUS Full-text
DOCUMENT NUMBER: 150:494705
TITLE: Design, synthesis, and structure-activity relationship of novel CCR2 antagonists
AUTHOR(S): Kothandaraman, Shankaran; Donnely, Karla L.; Butora, Gabor; Jiao, Richard; Pasternak, Alexander; Morriello, Gregori J.; Goble, Stephen D.; Zhou, Changyou; Mills, Sander G.; MacCoss, Malcolm; Vicario, Pasquale P.; Ayala, Julia M.; DeMartino, Julie A.; Struthers, Mary; Cascieri, Margaret A.; Yang, Lihu
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(6), 1830-1834
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 150:494705
ED Entered STN: 13 Mar 2009
GI



I

AB A series of novel 1-aminocyclopentyl-3-carboxamides incorporating substituted tetrahydropyran moieties have been synthesized and evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog I was found to posses potent antagonistic activity.

IT 1149374-71-9P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis, and structure-activity relationship of novel tetrahydropyranylaminocyclopentanecarboxamides as CCR2 antagonists)
RN 1149374-71-9 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(3R,4R)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 693247-22-2P 693247-24-4P 693247-26-6P
693247-28-8P 693247-30-2P 693247-32-4P
693247-34-6P 693247-40-4P 693247-43-7P
693247-45-9P 693247-47-1P 693247-49-3P
693247-53-9P 693247-57-3P 693247-61-9P
693247-63-1P 693247-65-3P 693247-70-0P
693247-72-2P 693247-74-4P 693247-76-6P
693247-78-8P 693273-54-0P 1149374-66-2P
1149374-67-3P 1149374-68-4P 1149374-69-5P
1149374-70-8P 1149374-72-0P 1149374-73-1P
1149374-74-2P 1149374-75-3P 1149374-76-4P
1151469-20-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis, and structure-activity relationship of novel tetrahydropyranylaminocyclopentanecarboxamides as CCR2 antagonists)

RN 693247-22-2 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-24-4 HCAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-26-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-28-8 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-4-C-(trifluoromethyl)-2,3-dideoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-30-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-propyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-32-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,3-dimethyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-34-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-40-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-

methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-43-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-45-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-47-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-oxepanylamino)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-49-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-furanyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-53-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-thienyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693247-57-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-61-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cycloheptylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-63-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 693247-65-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclobutylamino)-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 693247-70-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 693247-72-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-1-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-74-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-76-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-78-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2-methyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 693273-54-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,5-dimethyl-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1149374-66-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1149374-67-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1149374-68-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-piperidinylamino)-, hydrochloride (1:?), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 1149374-69-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1149374-70-8 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-2,3-dideoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1149374-72-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(3S,4S)-tetrahydro-3-methyl-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1149374-73-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3R,4R)-3-ethyltetrahydro-2H-pyran-4-yl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1149374-74-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3S,4S)-3-ethyltetrahydro-2H-pyran-4-yl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1149374-75-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3R,4R)-3-fluorotetrahydro-2H-pyran-4-yl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1149374-76-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(3S,4S)-3-fluorotetrahydro-2H-pyran-4-yl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1151469-20-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxetanylamino)-, (1S,3R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 693247-54-0
CMF C21 H26 F6 N2 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 693245-66-8P 860797-45-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis, and structure-activity relationship of novel tetrahydropyranylaminocyclopentanecarboxamides as CCR2 antagonists)
RN 693245-66-8 HCAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860797-45-1 HCAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, hydrochloride (1:1), (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:799448 HCAPLUS Full-text
DOCUMENT NUMBER: 141:314341
TITLE: Preparation of (tetrahydropyranylamino)cyclopentanecarbonyl-substituted fused azaheterocycles as modulators of cytokine receptors such as CCR2
INVENTOR(S): Goble, Stephen D.; Pasternak, Alexander; Mills, Sander G.; Zhou, Changyou; Yang, Lihu
PATENT ASSIGNEE(S): Merck & Co. Inc., USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082616	A2	20040930	WO 2004-US7831	20040312
WO 2004082616	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004222341	A1	20040930	AU 2004-222341	20040312
CA	2519297	A1	20040930	CA 2004-2519297	20040312
EP	1606280	A2	20051221	EP 2004-720505	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN	1826334	A	20060830	CN 2004-80013280	20040312
JP	2007524590	T	20070830	JP 2006-507192	20040312
IN	2005DN04099	A	20070831	IN 2005-DN4099	20050912
US	20060178363	A1	20060810	US 2005-550111	20050919
US	7393844	B2	20080701		

PRIORITY APPLN. INFO.: US 2003-456046P P 20030318
WO 2004-US7831 A 20040312

OTHER SOURCE(S): MARPAT 141:314341
ED Entered STN: 30 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [A = R82C, C(:O), NR8, O; B = R22C, O, S(:O), SO2, NSO2R14, NC(:O)R13, NC(:O)NR122,C(:O); D, X = C, N; E = (CH2)n; G = CH:CH, CH2CH2; Y = O, R12N, S, S(:O), SO2, R112C, etc.; n = 0-2; R1 = H, NC, (un)substituted alkyl, heterocyclyl, Ph, R122N, R13C(:O)N(R12), R14SO2N(R12), R11C(:O), R122NC(:O); R2 = H, alkyl, F, HO, heterocyclyl, R13C(:O)NH, etc.; R3, R4 = absent, H, (un)substituted alkyl, HO, Cl, O, etc.; R5 = (un)substituted alkyl, alkoxy, alkylcarbonyl, alkylthio, pyridyl, etc.; R8 = H, alkyl, (un)substituted alkylcarbonylalkyl; R11 = HO, H, (un)substituted alkyl, alkoxy, cycloalkyl, benzyl, phenyl; R12 = H, (un)substituted alkyl, benzyl, Ph, cycloalkyl; R13 = H, (un)substituted alkyl, alkoxy, benzyl, Ph, cycloalkyl; R14 = H, HO, (un)substituted alkyl, benzyl, Ph, cycloalkyl; R15 = H, (un)substituted alkyl; R16 = H, (un)substituted alkyl, alkoxy, cycloalkyl, F, HO, etc.; R17 = H, HO, (un)substituted alkyl, alkoxy, R11C(:O); R18 = H, F, (un)substituted alkyl, cycloalkoxy, alkoxy; R16 and either R17 or R18 may be joined in a ring] such as II are prepared as modulators of cytokine receptors such as CCR2 for the treatment of inflammatory and immune system disorders such as rheumatoid arthritis. Coupling of (tert-butoxy)(trifluoromethyl)benzylamine III and nonracemic (tetrahydropyranylamino)cyclopentanecarboxylic acid IV followed by cleavage of the tert-Bu group, cyclocondensation with paraformaldehyde, and cleavage of the trifluoroacetamide yields II as its hydrochloride salt. III is prepared by nucleophilic substitution of 2-fluoro-5-(trifluoromethyl)benzonitrile with potassium tert-butoxide followed by hydrogenation of the nitrile moiety. IV is prepared by Boc protection of the amine moiety of V, benzylation of the carboxylic acid group, cleavage of the Boc group, reductive amination of the amine with tetrahydropyran-4-one, trifluoroacetylation of the secondary amine, stereoselective alkylation of the ester with potassium bis(trimethylsilyl)amide and iso-Pr iodide, and hydrogenolysis of the benzyl ester; a second route to IV is also described. Compds. of the invention inhibit CCR2 with IC50 values of < 1 μM (no data).

IT 765297-58-3P 765297-59-4P 765297-61-8P
765297-63-0P 765297-71-0P 765297-72-1P
765297-76-5P 765297-77-6P 765297-78-7P
765297-79-8P 765297-84-5P 765297-85-6P
765297-90-3P 765297-91-4P 765297-93-6P
765298-02-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of (tetrahydropyranylamino)cyclopentanecarbonyl-substituted fused azaheterocycles as modulators of cytokine receptors such as CCR2 for the treatment of inflammatory and immune system diseases such as rheumatoid arthritis)

RN 765297-58-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-59-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-61-8 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetyloxy)ethyl]-N-[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-63-0 HCAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetyloxy)ethyl]-N-[[2-hydroxy-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-

trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-71-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-[(1,1-dimethylethyl)thio]-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-72-1 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-N-[[2-[(2-nitrophenyl)dithio]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-76-5 HCAPLUS
CN Cyclopentanecarboxamide, 1-[(1S)-1-(acetyloxy)ethyl]-N-[[2-[(1,1-dimethylethyl)thio]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-77-6 HCAPLUS
CN Cyclopentanecarboxamide, 1-[(1R)-1-(acetyloxy)ethyl]-N-[[2-[(1,1-dimethylethyl)thio]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-78-7 HCAPLUS
CN Cyclopentanecarboxamide, 1-[(1S)-1-(acetyloxy)ethyl]-N-[[2-[(2-nitrophenyl)dithio]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-79-8 HCAPLUS
CN Cyclopentanecarboxamide, 1-[(1R)-1-(acetyloxy)ethyl]-N-[[2-[(2-nitrophenyl)dithio]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-84-5 HCAPLUS
CN Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[[2-[(1,1-dimethylethyl)thio]-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl](trifluoroacetyl)amino]-4-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-85-6 HCAPLUS
CN Pentitol, 1,5-anhydro-2,3-dideoxy-4-O-methyl-3-[[(1R,3S)-3-(1-methylethyl)-3-[[[2-[(2-nitrophenyl)dithio]-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl](trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-90-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-amino-5-(trifluoromethyl)phenyl]methyl]-1-

(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-91-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-N-[[2-[(methylsulfonyl)amino]-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765297-93-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2-amino-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 765298-02-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[(5-chloro-2-hydroxyphenyl)methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:740293 HCAPLUS Full-text
DOCUMENT NUMBER: 141:260762
TITLE: Preparation of aminocyclopentyl fused heterotricyclic amide derivatives as modulators of chemokine receptor activity
INVENTOR(S): Goble, Stephen D.; Pasternak, Alexander; Tang, Cheng; Zhou, Changyou; Yang, Lihu
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076411	A2	20040910	WO 2004-US5297	20040223
WO 2004076411	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004215409	A1	20040910	AU 2004-215409	20040223
AU 2004215409	B2	20081120		
CA 2516705	A1	20040910	CA 2004-2516705	20040223
EP 1599206	A2	20051130	EP 2004-713725	20040223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518757	T	20060817	JP 2006-503800	20040223
US 20070004714	A1	20070104	US 2005-543794	20050811
US 7557120	B2	20090707		

PRIORITY APPLN. INFO.:		US 2003-449547P	P 20030224
		WO 2004-US5297	A 20040223

OTHER SOURCE(S): MARPAT 141:260762
ED Entered STN: 10 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I) [A = C, N; D, E = independently C, N, O, SO, or SO2, where by a fused carbocycle is formed if A, D and E are all C, where by a fused heterocycle is formed if at least one of A, D, or E is N, O, or S; X = O, N, S, SO2, C; R1 = H, C1-6 alkyl, C0-6 alkyl-O-C1-6 alkyl, C0-6 alkyl-S-C1-6 alkyl, C0-6 alkyl-C3-7 cycloalkyl-C0-6 alkyl, hydroxy, heterocycle, cyano, NH2, acylamino, sulfonylamino, acyl, CONH2, etc.; if D = C, then R2 = H, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if D = N, then R2 = H, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if D = O, SO, or SO2, then R2 is absent; if E = C, then R3 = H, HO, Cl, F, Br, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if E = N, then R3 = H, Ph, oxo, or (un)substituted C1-3 alkyl or alkoxy; R4 = Cl, F, Br, Ph, (un)substituted C1-3 alkyl or C1-3 alkoxy; R5 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkylthio, pyridyl, F, Cl, Br, C4-6 cycloalkyl, C4-6 cycloalkoxy, Ph, etc.; R6 = H, HO, Cl, F, Br, Ph, (un)substituted C1-3 alkyl or alkoxy, etc.; R7 = H, phenyl-, heterocyclyl-, C3-7 cycloalkyl-, acyl-, or sulfo-C0-6 alkyl, etc.; when X = O, then R7 is absent; R8 = H, HO, C1-6 alkyl, hydroxy-C1-6 alkyl, C1-3 alkoxy, acyl, NH2, cyano, etc.; R9, R10 = H, HO, C1-6 alkyl or alkoxy, benzyl, Ph, etc.; m, n = 0-2] and pharmaceutically acceptable salts thereof and individual diastereomers thereof are prepared These compds. are useful as modulators of the chemokine receptor CCR-2 and could be useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (no data). Thus, intermediate (II) was cyclocondensed with paraformaldehyde in the presence of p-MeC6H4SO3H in toluene under refluxing for 18 h with removal of water using a Dean-Stark trap to give the precursor (III; R = COCF3) which was treated with NaBH4 in ethanol at room temperature for 18 h to give, after HPLC purification and treatment with HCl/Et2O, III.xHCl (R = H).

IT 754241-65-1P 754241-66-2P 754241-67-3P
754241-70-8P 754241-72-0P 754241-74-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminocyclopentyl fused heterotricyclic amide derivs. as modulators of chemokine receptor activity)

RN 754241-65-1 HCAPLUS

CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-N-[[5-(trifluoromethyl)-1H-benzimidazol-7-yl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 754241-66-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2,3-dihydro-2-oxo-6-(trifluoromethyl)-1H-benzimidazol-4-yl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 754241-67-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[1,3-dihydro-2,2-dioxido-6-(trifluoromethyl)-2,1,3-benzothiadiazol-4-yl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 754241-70-8 HCAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-4-[[[[(1S,3R)-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]cyclopentyl]carbonyl]amino]methyl]-2-oxo-6-(trifluoromethyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 754241-72-0 HCAPLUS
CN 2,1,3-Benzothiadiazole-1(3H)-carboxylic acid, 4-[[[[(1S,3R)-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]cyclopentyl]carbonyl]amino]methyl]-6-(trifluoromethyl)-, phenylmethyl ester, 2,2-dioxide (CA INDEX NAME)

Absolute stereochemistry.



RN 754241-74-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[2,3-dihydro-1-methyl-2-oxo-6-(trifluoromethyl)-1H-benzimidazol-4-yl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Structure Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 15:14:18 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Nov 2009  VOL 151 ISS 19
FILE LAST UPDATED: 4 Nov 2009  (20091104/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L11
L1              STR
```




```
G1 C,N
```

Structure attributes must be viewed using STN Express query preparation.

```
L5          545 SEA FILE=REGISTRY SSS FUL L1
L7              STR
```



G1 C,N

```
Structure attributes must be viewed using STN Express query preparation.
L9          462 SEA FILE=REGISTRY SUB=L5 SSS FUL L7
L11           7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L9


=> S L11 NOT L21
L31           1 L11 NOT L21

=> FILE WPIX
FILE 'WPIX' ENTERED AT 15:14:35 ON 05 NOV 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED:          2 NOV 2009   <20091102/UP>
MOST RECENT UPDATE:           200970      <200970/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    mid-June 2009.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<
'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L24
L7              STR
```



G1 C,N

Structure attributes must be viewed using STN Express query preparation.
L23 131 SEA FILE=WPIX SSS FUL L7
L24 3 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L23/DCR

=> S L24 NOT L25
L32 0 L24 NOT L25

=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 15:14:54 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 151 ISS 17 (20091030/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090233972 17 SEP 2009
DE 102008014117 17 SEP 2009
EP 2100589 16 SEP 2009
JP 2009215171 24 SEP 2009
WO 2009116098 24 SEP 2009
GB 2457820 02 SEP 2009
FR 2928371 11 SEP 2009
RU 2366648 10 SEP 2009
CA 2653107 08 AUG 2009

The new MARPAT User Guide is now available at:
http://www.cas.org/support/stngen/stndoc/marpat.html.

=> D STAT QUE L29
L7 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.
L29 25 SEA FILE=MARPAT SSS FUL L7

100.0% PROCESSED 82488 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.32

=> DUP REM L31 L32 L29
L32 HAS NO ANSWERS
FILE 'HCAPLUS' ENTERED AT 15:15:06 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 15:15:06 ON 05 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
PROCESSING COMPLETED FOR L31
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L29
L33 26 DUP REM L31 L32 L29 (0 DUPLICATES REMOVED)
ANSWER '1' FROM FILE HCAPLUS
ANSWERS '2-26' FROM FILE MARPAT

=> D IBIB ED ABS HITSTR 1; D IBIB AB QHIT 2-26

L33 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1124588 HCAPLUS Full-text
DOCUMENT NUMBER: 142:69197
TITLE: CCR-2 antagonists for treatment of neuropathic pain
INVENTOR(S): Abbadie, Catherine; Lindia, Jill Ann; Wang, Hao
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110376	A2	20041223	WO 2004-US17499	20040602
WO 2004110376	A3	20050224		

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    US 20060205761       A1    20060914    US 2005-559701          20051206
PRIORITY APPLN. INFO.:                     US 2003-476391P     P  20030606
                                           US 2003-531637P     P  20031222
                                           WO 2004-US17499     W  20040602
OTHER SOURCE(S):         MARPAT 142:69197
ED   Entered STN:  23 Dec 2004
AB    The invention is directed to methods of treating neuropathic pain and other
      neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical
      composition containing CCR-2 antagonists.
IT   693273-50-6
     RL: PRPH (Prophetic)
        (CCR-2 antagonists for treatment of neuropathic pain)
RN   693273-50-6  HCAPLUS
CN   Cyclobutanecarboxylic acid, 3-[[(1R,3S)-3-[[[[3,5-
     bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-
     methylethyl)cyclopentyl]amino]-  (CA INDEX NAME)

Absolute stereochemistry.
```




```
IT   693246-04-7P    693246-05-8P    693246-06-9P
     693246-07-0P    693246-09-2P    693246-10-5P
     693246-11-6P    693246-17-2P    693246-18-3P
     693246-19-4P    693246-20-7P    693246-21-8P
     693246-22-9P    693246-23-0P    693246-24-1P
     693246-25-2P    693246-26-3P    693246-27-4P
     693246-28-5P    693246-29-6P    693246-30-9P
     693246-31-0P    693247-21-1P    693247-23-3P
     693247-25-5P    693247-27-7P    693247-29-9P
     693247-31-3P    693247-33-5P    693247-35-7P
     693247-37-9P    693247-39-1P    693247-42-6P
     693247-44-8P    693247-46-0P    693247-48-2P
     693247-50-6P    693247-52-8P    693247-54-0P
     693247-56-2P    693247-58-4P    693247-60-8P
     693247-62-0P    693247-64-2P    693247-66-4P
     693247-69-7P    693247-71-1P    693247-73-3P
     693247-75-5P    693247-77-7P    693247-79-9P
     693247-82-4P    693247-84-6P    693247-86-8P
     693247-88-0P    693247-90-4P    693247-92-6P
```

693247-94-8P 693247-96-0P 693247-98-2P
693248-00-9P 693248-01-0P 693273-47-1P
693273-48-2P 693273-53-9P 693273-55-1P
693273-57-3P 808144-59-4P 808144-60-7P
808144-61-8P 808144-62-9P 808144-63-0P
808144-64-1P 808144-65-2P 808144-66-3P
808144-67-4P 808144-68-5P 808144-69-6P
808144-70-9P 808144-71-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCR2 antagonists for treatment of neuropathic pain)

RN 693246-04-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(3-methoxyphenyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-05-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(3-methoxyphenyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-06-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(2-thienyl)- (CA INDEX NAME)



RN 693246-07-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(2-thienyl)- (CA INDEX NAME)



RN 693246-09-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-1-(3-thienyl)- (CA INDEX NAME)



RN 693246-10-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-phenyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-11-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-phenyl-3-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 693246-17-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-chloro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-18-3 HCAPLUS
CN Cyclopentanecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-19-4 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-20-7 HCAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-21-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693246-22-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-dichlorophenyl)methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-23-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-24-1 HCAPLUS
CN Pentitol, 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-hydroxy-1-methylethyl)cyclopentyl]amino]-, 4-(3-chlorobenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-25-2 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-26-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-27-4 HCAPLUS
CN Cyclopentanecarboxamide, 3-(cyclohexylamino)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693246-28-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-29-6 HCAPLUS
CN Cyclopentanecarboxylic acid, 3-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-30-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1-methyl-4-piperidinyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693246-31-0 HCAPLUS
CN Cyclopentanecarboxamide, 3-[(1-acetyl-4-piperidinyl)amino]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-21-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-23-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-25-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-27-7 HCAPLUS
CN Pentitol, 1,5-anhydro-3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-4-C-(trifluoromethyl)-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-29-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-propyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-31-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,3-dimethyl-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693247-33-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[tetrahydro-3-(trifluoromethyl)-2H-pyran-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-35-7 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-37-9 HCAPLUS
CN 2H-Pyran-3-carboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-39-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-42-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-44-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-46-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-oxepanylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-48-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-furanyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-50-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[(tetrahydro-3-furanyl)methyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-52-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3-thienyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-54-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-oxetanylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-56-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclohexylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-58-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methylcyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-60-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cycloheptylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-62-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-64-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(cyclobutylamino)-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-66-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(cyclobutylmethyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-69-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-2-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-71-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,3-dihydro-1H-inden-1-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-73-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693247-75-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-77-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2-methyl-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-79-9 HCAPLUS
CN Hexonic acid, 2,6-anhydro-4-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-3,4,5-trideoxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-82-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-84-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-piperidinylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-86-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-ethyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-88-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-90-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-cyclopropyltetrahydro-2H-pyran-4-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-92-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-pyran-3-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-94-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-2H-thiopyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693247-96-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693247-98-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-[(tetrahydro-3-methyl-2H-thiopyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693248-00-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[methyl(tetrahydro-3-methyl-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693248-01-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-fluorotetrahydro-2H-pyran-4-yl)methylamino]-1-(1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693273-47-1 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(1R,3S)-3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-48-2 HCAPLUS
CN Cyclobutanecarboxylic acid, 3-[[(1R,3S)-3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-53-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-3,5-dimethyl-2H-pyran-4-yl)amino]-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 693273-55-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-methylcyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 693273-57-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-hydroxycyclohexyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-59-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(phenylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-60-7 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-chlorophenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-61-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[4-(methylthio)phenyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-62-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[4-(methylsulfonyl)phenyl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-63-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-64-1 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4'-fluoro[1,1'-biphenyl]-4-yl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-65-2 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-chlorophenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-66-3 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-chlorophenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-67-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(2-methoxyphenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-68-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-methoxyphenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-69-6 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(4-methoxyphenyl)amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-70-9 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(2-pyridinylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808144-71-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-pyridinylamino)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 150:563480 MARPAT Full-text
TITLE: Preparation of naphthalenylethyl-cyclopentylamine and -cyclohexylamine derivatives as modulators of calcium sensing receptor (CaSR)
INVENTOR(S): Fensholdt, Jef; Havez, Sophie Elisabeth; Noerremark, Bjarne
PATENT ASSIGNEE(S): LEO Pharma A/S, Den.
SOURCE: PCT Int. Appl., 216pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009065406	A2	20090528	WO 2008-DK410	20081120
WO 2009065406	A3	20090911		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-989856P 20071123
US 2008-92553P 20080828

AB Title compds. I [ring X = (un)substituted cycloalkyl; A = (un)substituted heteroaryl, aryl or heterocycloalkylaryl, R1 = (un)substituted alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, etc.; R2 and R3 independently = H, CN, halo, carboxy, C(O)NH2, etc.; R4 = H, halo, OH, carboxy, NH2, etc.; R5 independently = H, halo, OH, carboxy, NH2, etc.; G = H, C(O)H, C(O)NH2, OC(O)NH2, alkyl, etc.], and their pharmaceutically acceptable salts, solvates or in vivo hydrolyzable esters, are prepared and disclosed. Thus, e.g., reaction of 3-(4-cyanophenyl)cyclohexanone with (+)-[(R)-1-(naphthalen-1-yl)ethyl]amine to

gave 4-[3-[[(R)-1-(naphthalen-1-yl)ethyl]amino]cyclohexyl]benzonitrile which was subsequently treated with 28% aqueous NaOH under refluxing overnight gave II. II exhibited IC50 value of 250 nM in vitro in CaSR functional whole cell assay. As potent modulators of CaSR, I should prove useful in the treatment of diseases related to kidneys or bones.

MSTR 1B



G1 = 26

G3 = 21

G26 = cycloalkyl <containing 3-6 C> (opt. substd.)
G33 = 133

G50 = 205

G54 = 225

G56 = phenylene
Patent location: claim 1

Note: or pharmaceutically acceptable salts, solvates, or in vivo hydrolyzable esters
Note: additional derivatization also claimed
Note: substitution is restricted

L33 ANSWER 3 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 149:576275 MARPAT Full-text
TITLE: Preparation of indanylthiourea derivatives and analogs as pesticides
INVENTOR(S): Koradin, Christopher; Kordes, Markus; Baumann, Ernst; Vezouet, Ronan Le; Culbertson, Deborah L.
PATENT ASSIGNEE(S): BASF SE, Germany
SOURCE: PCT Int. Appl., 178pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008141980	A1	20081127	WO 2008-EP55851	20080513

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-939931P 20070524

AB Title compds. I [X = O, S, S(O), etc.; Y = bond or CH2; R1 = H, C(O)R7, or C(S)R7; R2 and R3 independently = H, CN, NO2, etc.; or R2 together with R1 may be bridging C=O or C=S group, etc.; R4 = H, CN, alkyl, etc.; each R5 independently = H, halo, OH, NO2, etc.; each R6 independently = H, OH, SH, NH2, etc.; R7 = H, (un)substituted alkyl, alkoxy, etc.; n = 0 to 4], and their pharmaceutically acceptable salts, are prepared and disclosed as pesticides. Thus, e.g., II was prepared by addition of 2-aminoethanol with 5-Fluoro-2,3-dihydro-3-isothiocyanatobenzofuran. Select I were evaluated in cotton aphid mortality assays, e.g., II demonstrated at least 75% mortality at 300 ppm.

MSTR 1



G1 = 72

G2 = bond
G4 = O
G7 = 77

G12 = NH
G19 = 53

G20 = NO2
G21 = 56

G22 = NH
G29 = Ph
G41 = 118

Patent location: claim 1
Note: substitution is restricted
Note: or salts
Note: additional derivatization also claimed
Stereochemistry: or enantiomers or diastereomers

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 4 OF 26 MARPAT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 149:79623 MARPAT Full-text
TITLE: Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents and their preparation and use in the treatment of diseases
INVENTOR(S): Terasaka, Tadashi; Zenkoh, Tatsuya; Hayashida, Hisashi; Matsuda, Hiroshi; Sato, Junji; Imamura, Yoshimasa; Nagata, Hiroshi; Seki, Norio; Tenda, Yoshiyuki; Tasaki, Mamoru; Takeda, Masahiro; Tabuchi, Seiichiro; Yasuda, Minoru; Tsubaki, Kazunori
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 265pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008072784	A1	20080619	WO 2007-JP74475	20071213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2672601	A1	20080619	CA 2007-2672601	20071213
EP 2094662	A1	20090902	EP 2007-859872	20071213
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2009096690	A	20090914	KR 2009-708871	20071213
PRIORITY APPLN. INFO.:			US 2006-870014P	20061214
			WO 2007-JP74475	20071213

AB The invention relates to compds. of formula I or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, Hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like. Compds. of formula I wherein if dashed bond is single and double bond then ring A is (un)substituted pyridinone, (un)substituted pyridazinone, (un)substituted oxazolidinone, (un)substituted thiazolidinone, (un)substituted imidazolidinone, etc.; if dashed bond is absent then A indicates acyclic amide derivs.; Y1 and Y2 are independently C1-6 (hetero)alkylene, and C2-6 (hetero)alkenylene; E1 is H and (un)substituted phenyl; E2 is (un)substituted Ph and (un)substituted xanthenyl; E3 is (un)substituted (un)fused benzene ring; R4 is H, C1-6 alkyl and alkali methyl; n is 0 and 1; and their pharmaceutically acceptable salts and prodrugs thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their CRTH2 antagonisitic and antiallergic activities (no data).

MSTR 1



G1 = 66-2 67-6

G7 = cyclopentyl (opt. substd. by 1 or more G8)
G8 = 363 / 367

G9 = (1-2) CH2
G13 = Ph (opt. substd. by 1 or more G17)
Patent location: claim 1
Note: or pharmaceutically acceptable salts or prodrugs
Note: additional derivitization also claimed

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 148:262252 MARPAT Full-text
TITLE: Cyclopentanecarboxylic acid derivatives and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections
INVENTOR(S): Orchard, Michael Glen; Benghezal, Mohammed; Braillard, Stephanie; Burn, Christine; Deuschel, Christine; Lucas, Aurore; Valentino, Emilio; Janssen, Christian; Boyce, Rustum S.
PATENT ASSIGNEE(S): Merlion Pharmaceuticals S.A., Switz.; Merlion Pharmaceuticals Pte Ltd.
SOURCE: PCT Int. Appl., 62pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008017840	A1	20080214	WO 2007-GB3017	20070808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-836126P 20060808

OTHER SOURCE(S): CASREACT 148:262252

AB The invention relates to cyclopentanecarboxylic acid derivs. of formula I, and related compds., processes for the preparation thereof, pharmaceutical compns. containing the same, the use thereof optionally in combination with one or more other pharmaceutically active compds. as antibacterial agents for the therapy of infective diseases, and a method for the treatment of such diseases. The compds. of formula I are reducing selectively the pathogenicity of bacteria within the host, but without affecting the bacteria outside the host environment. Compds. of formula I wherein R1 is (un)substituted (hetero)arylaminocarbonyl, (un)substituted aryl-lower alkylaminocarbonyl, (di)alkylaminocarbonyl, heterocyclylaminocarbonyl, (un)substituted arylamino, etc.; R2 and R5 are independently H, Me, OH, lower alkyloxy, heterocyclyloxy, (un)substituted aryloxy, etc.; R3 and R4 are independently H and lower alkyl; R3 and R4 taken together forms C3-6 alkylene; R6 is OH, lower alkyloxy, lower heterocyclyloxy and amino and derivs.; and their salts thereof, are claimed. The example compound II was prepared by amidation of (±)-camphoric acid anhydride with 3-(trifluoromethoxy)aniline. All the invention compds. were evaluated for their antibacterial activity. From the assay, it was determined that example compound II exhibited an IC50 value of 12 μM.

MSTR 1

G1 = 14

G2 = 86

G4 = NH2 / heterocycle <containing zero or more N, zero or more O, zero or more S>
G7 = 40

Patent location: claim 1
Note: and salts

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 147:117972 MARPAT Full-text
TITLE: Preparation of 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
INVENTOR(S): Xue, Chu-Biao
PATENT ASSIGNEE(S): Incyte Corporation, USA
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007072201	A2	20070628	WO 2006-IB3739	20061218
WO 2007072201	A3	20071004		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006327823	A1	20070628	AU 2006-327823	20061218
CA 2634636	A1	20070628	CA 2006-2634636	20061218
EP 1971576	A2	20080924	EP 2006-831787	20061218
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009520809	T	20090528	JP 2008-546684	20061218
NL 2000380	A1	20070625	NL 2006-2000380	20061219
NL 2000380	C2	20071128		
US 20070149532	A1	20070628	US 2006-613330	20061220
NO 2008002285	A	20080618	NO 2008-2285	20080519
MX 2008006765	A	20080708	MX 2008-6765	20080526
IN 2008DN04984	A	20080808	IN 2008-DN4984	20080610
KR 2008070868	A	20080731	KR 2008-714972	20080620

CN 101341123 A 20090107 CN 2006-80048234 20080620
PRIORITY APPLN. INFO.: US 2005-752320P 20051221
US 2005-752477P 20051221
WO 2006-IB3739 20061218

OTHER SOURCE(S): CASREACT 147:117972

AB Cyclopentanecarboxamides of formula I [W = (substituted) piperidine, piperazine; V, X, Y, Z = N, NO, (substituted) CH; L = alkylene, CO, CONH, SO2, etc.; R1 = alkyl, OH, acyl, etc.; R2 = H, OH, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, etc.; R4 = alkyl, aryl, cycloalkyl, heteroaryl, etc.] are prepared as modulators of chemokine receptors. The compds. of the invention, and compns. thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity. Thus, II was prepared, and had IC50 value of 19.8 nM against CCR2.

MSTR 1



G8 = CH2Ph
G12 = 69

G14 = 100

Patent location: claim 1
Note: or pharmaceutically acceptable salts or prodrugs
Note: or N-oxides
Note: additional ring formation also claimed

L33 ANSWER 7 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 144:108363 MARPAT Full-text
TITLE: Preparation of tetrahydropyranyl- and piperazinyl/piperidinyl/tetrahydropyridinyl-substituted 3-aminocyclopentanecarboxamides as antagonists of chemokine receptors CCR2 and CCR5
INVENTOR(S): Xue, Chu-Biao; Zheng, Changsheng; Feng, Hao; Xia, Michael; Glenn, Joseph; Cao, Ganfeng; Metcalf, Brian W.
PATENT ASSIGNEE(S): Incyte Corporation, USA
SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004741	A2	20060112	WO 2005-US22909	20050627
WO 2006004741	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005259983	A1	20060112	AU 2005-259983	20050627
AU 2005260013	A1	20060112	AU 2005-260013	20050627
CA 2571019	A1	20060112	CA 2005-2571019	20050627
CA 2571397	A1	20060112	CA 2005-2571397	20050627
US 20060020133	A1	20060126	US 2005-167329	20050627
EP 1763347	A2	20070321	EP 2005-787815	20050627
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
EP 1763351	A2	20070321	EP 2005-790938	20050627
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1976707	A	20070606	CN 2005-80021461	20050627
CN 1976702	A	20070606	CN 2005-80021744	20050627
JP 2008504293	T	20080214	JP 2007-518357	20050627
JP 4116670	B2	20080709		
JP 2008504298	T	20080214	JP 2007-518367	20050627
JP 4116671	B2	20080709		
BR 2005012352	A	20080304	BR 2005-12352	20050627
BR 2005012634	A	20080325	BR 2005-12634	20050627
IN 2006DN06984	A	20070713	IN 2006-DN6984	20061122
IN 2006DN06983	A	20070803	IN 2006-DN6983	20061122
ZA 2006010426	A	20080730	ZA 2006-10426	20061212
MX 2006014672	A	20070326	MX 2006-14672	20061214
MX 2006014673	A	20070326	MX 2006-14673	20061214
ZA 2006010667	A	20080625	ZA 2006-10667	20061218
KR 2007024659	A	20070302	KR 2006-727483	20061227
KR 856155	B1	20080903		
KR 856156	B1	20080903	KR 2006-727464	20061227
NO 2007000487	A	20070305	NO 2007-487	20070125
NO 2007000489	A	20070307	NO 2007-489	20070125
JP 2008074877	A	20080403	JP 2007-321252	20071212
JP 2008074878	A	20080403	JP 2007-321338	20071212
US 20090208485	A1	20090820	US 2009-432040	20090429
PRIORITY APPLN. INFO.:			US 2004-583482P	20040628
			US 2004-624481P	20041101
			US 2004-624374P	20041101

	JP 2007-518357	20050627
	JP 2007-518367	20050627
	US 2005-167329	20050627
	WO 2005-US22793	20050627
	WO 2005-US22909	20050627

OTHER SOURCE(S): CASREACT 144:108363

AB The present invention is directed to 3-aminocyclopentanecarboxamides (shown as I; variables defined below; e.g. N-[(1R,3S)-3-isopropyl-3-[[4-[3-(trifluoromethyl)phenyl]piperazin-1- yl]carbonyl]cyclopentyl]-3-methoxytetrahydro-2H-pyran-4-amine (shown as II)) that are antagonists of chemokine receptors CCR2 and CCR5. The compds. of the invention, and compns. thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity. Although the methods of preparation are not claimed, prepns. and/or characterization data for .apprx.30 examples of I are included. For example, II was prepared in 10 steps; earlier steps describe the preparation of 3-methoxytetrahydro-4H-pyran-4-one and (1R,3S)-3-[[4-[3-(trifluoromethyl)phenyl]piperazin-1- yl]carbonyl]cyclopentanamine bis(trifluoroacetate), which react in the presence of Et3N and sodium triacetoxyborohydride to give II (92 % for this step). For I: a dashed line indicates an optional bond; W is divalent piperazine, tetrahydropyridine or piperidine; V is N, NO or CR5; X is N, NO or CR2; Y is N, NO or CR3; Z is N, NO or CR4; wherein no more than one of V, X, Y and Z is NO; R1 is C1-6 alkyl, C1-6-haloalkyl, C1-6 hydroxyalkyl, -(C0-6 alkyl)-O-(C1-6 alkyl), -(C0-6 alkyl)-S-(C1-6 alkyl), -(C0-6 alkyl)-(C3-7 cycloalkyl)-(C0-6 alkyl), OH, OR10, SR10, COR11, CO2R10, CONR10R12, carbocyclyl, heterocyclyl, CN, NR10R12, NR10SO2R10, NR10COR10, NR10CO2R10, NR10CONR12, CR10R11CO2R10 or CR10R11OCOR10; R2, R3, R4, R5 and R6 = H, OH, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, NR10R12, NR10CO2R11, NR10CONR10R12, NR10SO2NR10R12, NR10-SO2-R11, heterocyclyl, carbocyclyl, carbocycloxy, heterocycloxy, CN, NO2, COR11, CONR10R12, CO2R10, NO2, SR10, SOR10, SO2R10; or SO2NR10R12; R7 is H or (un)substituted C1-6 alkyl; R8 is C1-3 alkoxy, C1-3 haloalkoxy, C3-6 cycloalkyloxy or OH; R8' is H; R9 and R9' = H, C1-6 alkyl, halo, C1-3 alkoxy, C1-3 haloalkoxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, OH, CO2R10, OCOR10; or R9 and R9' together with the C atom to which they are attached form a 3-7 membered spirocyclyl group; addnl. details are given in the claims.

MSTR 1



G8 = CH2Ph
G12 = 69

G14 = 100

1660-312

Patent location: claim 1
Note: or pharmaceutically acceptable salts or prodrugs
Note: or N-oxides

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 8 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 144:128984 MARPAT Full-text
TITLE: Preparation of phthalazine derivatives as PARP inhibitors
INVENTOR(S): Mevellec, Laurence Anne; Kennis, Ludo Edmond Josephine; Mertens, Josephus Carolus; Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006003147	A1	20060112	WO 2005-EP53030	20050628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005259189	A1	20060112	AU 2005-259189	20050628
CA 2569824	A1	20060112	CA 2005-2569824	20050628
EP 1771175	A1	20070411	EP 2005-761151	20050628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1980674	A	20070613	CN 2005-80022258	20050628
JP 2008504348	T	20080214	JP 2007-518607	20050628
BR 2005012902	A	20080415	BR 2005-12902	20050628
SG 154433	A1	20090828	SG 2009-4450	20050628
US 20080139568	A1	20080612	US 2006-569889	20061201
MX 2006014542	A	20070323	MX 2006-14542	20061213
ZA 2006010774	A	20080625	ZA 2006-10774	20061220
IN 2006DN07960	A	20070427	IN 2006-DN7960	20061228
KR 2007029246	A	20070313	KR 2007-700397	20070108
NO 2007000557	A	20070130	NO 2007-557	20070130

PRIORITY APPLN. INFO.: EP 2004-76886 20040630
WO 2005-EP53030 20050628

OTHER SOURCE(S): CASREACT 144:128984

AB Title compds. I [n = 0-3; Q = -CO-, -CR3-; R3 = halo, alkyl; when Q is -CR3-, the dotted line represents a bond; X = N, CH; when X is CH, then Y is N or NH; Y = N, NH, CH, etc.; except when X is CH, then Y is N or NH; L1 = direct bond, bivalent radical selected from -alkanediyl-NH-, -NH-, -NH-alkanediyl-NH-; L2 = direct bond, bivalent radical selected from -alkanediyl-, -alkanediyl-carbonyl, -alkanediyl- substituted with one substituent selected from hydroxy or aryl; R1 = H, nitro, halo, etc.; R2 = H, alkyl, arylalkyl; Q1 may be bridged, e.g., forming a bicyclic moiety, with an ethylene bridge; Z =H, hydroxy, alkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, reaction of 1(3H)-isobenzofuranone with 1-benzyl-4-piperidinone followed by treating with hydrazine monohydrate afforded compound II. In PARP-1 (poly(ADP-ribose)polymerase-1) inhibition assays, the pIC50 value of compound II was 7.26. Compds. I are claimed useful as PARP inhibitors.

MSTR 1

G1 = (0-3) 41

G2 = 20

G3 = alkyl <containing 1-6 C>
(opt. substd. by Ph (opt. substd.))
G4 = 2-340 5-318

G8 = NH
G10 = C(O)
G12 = alkylamino <containing 1-6 C>
(substd. by Ph (opt. substd.))
G24 = 7



G26 = 18

G29 = 22

Patent location: claim 1
Note: and N-oxide forms
Note: substitution is restricted
Note: also incorporates claim 12
Stereochemistry: and stereochemically isomeric forms

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 9 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 146:49762 MARPAT Full-text
TITLE: Anti-parakeratosis agents, skin pore-shrinking agents, and rough skin-improving/preventing agents containing α-amino acid derivatives
INVENTOR(S): Kaneko, Maki; Iida, Toshiyuki; Inomata, Shinji; Uenuma, Mikiko; Suetsugu, Masaru
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006327972	A	20061207	JP 2005-151987	20050525

PRIORITY APPLN. INFO.: JP 2005-151987 20050525

AB The invention provides an agent for inhibiting parakeratosis, shrinking skin pores, and preventing/ameliorating rough skin, characterized by containing α-amino acid derivative R4(R3)NC(R1)(R2)COOH (R1 = H, Me; R2 = H, Me, Ch2OH; R3, R4 = H, C1-3 alkyl; allyl, carbobenzyloxy, acetyl, etc) or its salt. For example, a cosmetic lotion composition containing 1,3-butylene glycol 6, glycerin 4, oleyl alc. 0.1, polyoxyethylene sorbitan monolaurate 0.5,

polyoxyethylene lauryl alc. ester 0.5, ethanol 10, N-Me Me alanine 3, and water balance to 100 % was formulated.

MSTR 1

G3 = 10

G4 = 13

G5 = (0-2) CH2
G6 = cyclopentyl (opt. substd. by (1-9) G7) /
Ph (opt. substd. by 1 or more G7)
G7 = NH2 / CF3
Patent location: claim 1
Note: and salts
Note: substitution is restricted

L33 ANSWER 10 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 144:69736 MARPAT Full-text
TITLE: Preparation of tetrahydropyranyl cyclopentylcarboxamide modulators of chemokine receptor activity
INVENTOR(S): Yang, Lihu; Mills, Sander G.; Jiao, Richard
PATENT ASSIGNEE(S): Merck & Co., Inc, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120505	A2	20051222	WO 2005-US13754	20050422
WO 2005120505	A3	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU	2005251678	A1	20051222	AU 2005-251678	20050422
CA	2564499	A1	20051222	CA 2005-2564499	20050422
EP	1742915	A2	20070117	EP 2005-784477	20050422
CN	1972913	A	20070530	CN 2005-80013054	20050422
JP	2007534756	T	20071129	JP 2007-510819	20050422
IN	2006DN06022	A	20070831	IN 2006-DN6022	20061016
US	20080021061	A1	20080124	US 2006-587288	20061023
US	7557124	B2	20090707		

PRIORITY APPLN. INFO.: US 2004-565380P 20040426
WO 2005-US13754 20050422

OTHER SOURCE(S): CASREACT 144:69736

AB Title compds. I [Y = O, S, SO2, (un)substituted amino, etc.; Z = C or N; R1 = sulfonylalkyl, alkylamino, sulfonylamino, etc.; R2 = H, OH, halo, alkyl, etc.; R3 = H, (fluoro)alkyl, hydroxy, etc.; ; R4 = H, (fluoro)alkyl, Ph, etc.; R5 = alkyl, alkoxy, pyridyl, etc.; R6 = H, alkyl, Ph, etc.; R7 = H or (un)substituted alkyl; R8 = H, OH, F, etc., or R7R8 = cyclyl; R9 = H, OH, (un)substituted alkyl, alkyloxy, etc., or R8R9 = cyclyl; R10 = H, F, cycloalkyloxy, (un)substituted alkyloxy, (fluoro)alkyl, or R8R10 = cyclyl; R15, R16 = independently H, OH, (un)substituted alkyl, etc.; n = 0-2] and their pharmaceutically acceptable salts were prepared and disclosed as modulators of chemokine receptor activity (no data). Thus, II was prepared by condensation of tetrahydro-4H-pyran-4-one with the corresponding amino cyclopentyl precursor (preparation given). These compds. are useful as modulators of the chemokine receptor for the prevention or treatment of certain inflammatory and immunoregulatory disorders, such as rheumatoid arthritis (no data).

MSTR 1



G1 = 625

G7 = 2

G12 = 603



G19 = NH
G20 = 564

G55 = alkylene <containing 1-3 C>
Patent location: claim 1
Note: and pharmaceutically acceptable salts
Note: additional substitution also claimed
Stereochemistry: and diastereomers and enantiomers

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 11 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:460134 MARPAT Full-text
TITLE: Preparation of 3,3-disubstituted tetrahydropyranyl cyclopentyl amides as modulators of chemokine receptor
INVENTOR(S): Yang, Lihu; Mills, Sander G.; Shankaran, Kothandaraman
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105092	A2	20051110	WO 2005-US13752	20050422
WO 2005105092	A3	20070726		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

AU 2005237500	A1	20051110	AU 2005-237500	20050422
CA 2564561	A1	20051110	CA 2005-2564561	20050422
EP 1755603	A2	20070228	EP 2005-741852	20050422

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

JP 2007534755	T	20071129	JP 2007-510818	20050422
CN 101103027	A	20080109	CN 2005-80013591	20050422
IN 2006DN06118	A	20070831	IN 2006-DN6118	20061019
US 20080021057	A1	20080124	US 2006-587448	20061024
US 7566726	B2	20090728		

PRIORITY APPLN. INFO.: US 2004-566012P 20040428
WO 2005-US13752 20050422

OTHER SOURCE(S): CASREACT 143:460134

AB Title compds. I [X = (CH2)n; Y = O, S, SO, etc.; Z = C or N; R1 = H, OH, CN, etc.; R2 = H, halo, OH, etc.; R3 = H, (un)substituted alkyl or -O-alkyl if Z = C and R3 = O or is absent if Z = N; R4 = H or (un)substituted alkyl; R5 = (un)substituted alkyl, -O-alkyl, -CO-alkyl, etc.; R6 = H, (un)substituted alkyl or -O-alkyl; R7 = H or (un)substituted alkyl; R8 = (un)substituted alkyl and -O-alkyl or R7 and R8 together are alkyl or alkyl-O-alkyl forming a 5-7 membered ring; R9 = H, (un)substituted alkyl and -O-alkyl or R8 and R9 together are alkyl or alkyl-O-alkyl forming a 3-6 membered ring; R10 = H, (un)substituted alkyl and -O-alkyl or R8 and R10 together are (un)substituted alkyl-O-alkyl, -O-alkyl-O- or alkyl and are forming ring; R15 H, (un)substituted -O-alkyl or alkyl; R16 = H, F or (un)substituted alkyl; R17 = (un)substituted alkyl, -O-alkyl or cycloalkyl; R18 = H, (un)substituted alkyl or -O-alkyl; R17 and R8 together may form bridge; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of chemokine receptor. Thus, e.g., II was prepared by coupling of 3-hydroxy-3-methyl-tetrahydropyran-4-one with III (preparation given). The receptor affinity of I was evaluated by measuring the inhibition of 125I-MCP-1 to the endogenous CCR-2 receptor on various cell types including monocytes or THP-1 cells (no data). I as modulator of chemokine receptor should prove useful in the treatment of rheumatoid arthritis and inflammatory disorders. Pharmaceutical compns. comprising I are disclosed.

MSTR 1



G1 = 86

G9 = (0-2) CH2
G12 = CH2Ph (opt. substd.)
G34 = NH
Patent location: claim 1
Note: additional ring and oxo formation also claimed
Note: and pharmaceutically acceptable salts
Stereochemistry: or diastereomers

L33 ANSWER 12 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:172854 MARPAT Full-text
TITLE: Alkylamino, arylamino, and sulfonamido cyclopentane amide modulators of chemokine receptor activity
INVENTOR(S): Goble, Stephen D.; Yang, Lihu; Zhou, Changyou; Kothandaraman, Shankaran; Guiadeen, Deodialsingh; Butora, Gabor; Pasternak, Alexander; Mills, Sander G.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005067502	A2	20050728	WO 2004-US43777	20041229
WO 2005067502	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004313486	A1	20050728	AU 2004-313486	20041229
CA 2551869	A1	20050728	CA 2004-2551869	20041229
EP 1701724	A2	20060920	EP 2004-815779	20041229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1897941	A	20070117	CN 2004-80038562	20041229
JP 2007519633	T	20070719	JP 2006-547521	20041229
IN 2006DN03272	A	20070420	IN 2006-DN3272	20060607
US 20070117797	A1	20070524	US 2006-585232	20060630
PRIORITY APPLN. INFO.:			US 2004-533892P	20040102
			WO 2004-US43777	20041229

OTHER SOURCE(S): CASREACT 143:172854
AB Title compds. I [Z = N, C, where no more than two Z are N; R1 = OH, CN, (un)substituted alkyl/alkyl, Ph, etc.; when Z attached to R2 is N, R2 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; when Z attached to R3 is N, R3 = absent or O; and when Z attached to R3 is C, R3 = H, OH, halo, (un)substituted alkyl, etc.;when Z attached to R4 is N, R4 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; R5 = (un)substituted alkyl, alkylcarbonyl, Ph, etc.; when Z attached to R6 is N, R4 = absent or O; and when Z attached to R6 is C, R6 = H,

(un)substituted alkyl, alkoxy; R7 = H, (un)substituted alkyl, Ph, heterocyclyl; R8 = (un)substituted alkyl, Ph, pyridyl, etc.; R10, R16 = independently (:O), H, Ph, (un)substituted alkyl; R15 = H, alkyl; or R2 and R15 join together to form a carbocycle or heterocycle; X = (CH2)n; n = 0-1; and their pharmaceutically acceptable salts and individual diastereomers] were prepared as chemokine receptor, particularly CCR2, modulators. For example, II was prepared in 3 steps starting from 3-trifluoromethyl-5,6,7,8-tetrahydro-1,6-naphthyridine (preparation given). I bound to CCR2 receptor in a binding and chemotaxis assay with an IC50 of less than about 1 μM. The invention is directed to the pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, rheumatoid arthritis, etc. (no data).

MSTR 1



G1 = Ph (opt. substd.)
G9 = NH
G10 = 17

G11 = 310

G16 = CH2CH2
G53 = C(O)
G55 = 20

Patent location: claim 1
Note: additional ring formation also claimed
Note: and pharmaceutically acceptable salts
Stereochemistry: and individual diastereomers

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 13 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 142:240424 MARPAT Full-text
TITLE: Preparation of (thiazolyl)cyclopentane amide modulators of chemokine receptor activity
INVENTOR(S): Butora, Gabor; Yang, Lihu; Goble, Stephen D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014537	A2	20050217	WO 2004-US25467	20040806
WO 2005014537	A3	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004263509	A1	20050217	AU 2004-263509	20040806
CA 2534294	A1	20050217	CA 2004-2534294	20040806
EP 1654256	A2	20060510	EP 2004-780322	20040806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1832943	A	20060913	CN 2004-80022756	20040806
JP 2007501795	T	20070201	JP 2006-522756	20040806
IN 2006DN00519	A	20070810	IN 2006-DN519	20060131
US 20060205783	A1	20060914	US 2006-567516	20060207
US 7589085	B2	20090915		
PRIORITY APPLN. INFO.:			US 2003-493902P	20030808
			WO 2004-US25467	20040806

OTHER SOURCE(S): CASREACT 142:240424

AB Title compds. I [wherein Z = independently C or N; R1 = (alkoxy)alkyl, alkylthioalkyl, hydroxy, etc.; R2-R4, R6 = independently H, OH, alkyl, halo, etc.; R5 = (carbonyl)alkyl, CF3, halo, etc.; R7, R9 = independently H, Ph, alkyl, etc.; R8 = H, Ph, alkyl, etc.; R10 = (un)substituted tetrahydropyranyl-4-ylamino, azacyclohept-1-yl, azacyclooct-1-yl; and pharmaceutically acceptable salts or solvates thereof and individual diastereomers thereof] are prepd as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from 2,6-dichloro-4-trifluoromethylpyridine. The invention is directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. as chemokine receptor modulators in the prevention or treatment of the diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).

MSTR 1



G1 = Ph (opt. substd.)
G14 = 224



G52 = Ph
G53 = C(O) / 231

Patent location: claim 1
Note: additional ring formation also claimed
Note: and pharmaceutically acceptable salts
Stereochemistry: and individual diastereomers

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 141:260762 MARPAT Full-text
TITLE: Preparation of aminocyclopentyl fused heterotricyclic amide derivatives as modulators of chemokine receptor activity
INVENTOR(S): Goble, Stephen D.; Pasternak, Alexander; Tang, Cheng; Zhou, Changyou; Yang, Lihu
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076411	A2	20040910	WO 2004-US5297	20040223
WO 2004076411	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004215409	A1	20040910	AU 2004-215409	20040223	
AU 2004215409	B2	20081120			
CA 2516705	A1	20040910	CA 2004-2516705	20040223	
EP 1599206	A2	20051130	EP 2004-713725	20040223	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006518757	T	20060817	JP 2006-503800	20040223	
US 20070004714	A1	20070104	US 2005-543794	20050811	
US 7557120	B2	20090707			
PRIORITY APPLN. INFO.:			US 2003-449547P	20030224	
			WO 2004-US5297	20040223	

AB The title compds. (I) [A = C, N; D, E = independently C, N, O, SO, or SO2, where by a fused carbocycle is formed if A, D and E are all C, where by a fused heterocycle is formed if at least one of A, D, or E is N, O, or S; X = O, N, S, SO2, C; R1 = H, C1-6 alkyl, C0-6 alkyl-O-C1-6 alkyl, C0-6 alkyl-S-C1-6 alkyl, C0-6 alkyl-C3-7 cycloalkyl-C0-6 alkyl, hydroxy, heterocycle, cyano, NH2, acylamino, sulfonylamino, acyl, CONH2, etc.; if D = C, then R2 = H, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if D = N, then R2 = H, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if D = O, SO, or SO2, then R2 is absent; if E = C, then R3 = H, HO, Cl, F, Br, Ph, oxo, (un)substituted C1-3 alkyl or alkoxy; if E = N, then R3 = H, Ph, oxo, or (un)substituted C1-3 alkyl or alkoxy; R4 = Cl, F, Br, Ph, (un)substituted C1-3 alkyl or C1-3 alkoxy; R5 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkylthio, pyridyl, F, Cl, Br, C4-6 cycloalkyl, C4-6 cycloalkoxy, Ph, etc.; R6 = H, HO, Cl, F, Br, Ph, (un)substituted C1-3 alkyl or alkoxy, etc.; R7 = H, phenyl-, heterocyclyl-, C3-7 cycloalkyl-, acyl-, or sulfo-C0-6 alkyl, etc.; when X = O, then R7 is absent; R8 = H, HO, C1-6 alkyl, hydroxy-C1-6 alkyl, C1-3 alkoxy, acyl, NH2, cyano, etc.; R9, R10 = H, HO, C1-6 alkyl or alkoxy, benzyl, Ph, etc.; m, n = 0-2] and pharmaceutically acceptable salts thereof and individual diastereomers thereof are prepared These compds. are useful as modulators of the chemokine receptor CCR-2 and could be useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (no data). Thus, intermediate (II) was cyclocondensed with paraformaldehyde in the presence of p-MeC6H4SO3H in toluene under refluxing for 18 h with removal of water using a Dean-Stark trap to give the precursor (III; R = COCF3) which was treated with NaBH4 in ethanol at room temperature for 18 h to give, after HPLC purification and treatment with HCl/Et2O, III.xHCl (R = H).

MSTR 1A



G9 = 4-6 2-31 4-32

G11 = 64



G12 = CH2Ph (opt. substd.)
G19 = 193

Patent location: claim 1
Note: and pharmaceutically acceptable salts
Note: additional derivatization also claimed
Note: also incorporates broader disclosure
Stereochemistry: and individual diastereomers

MSTR 1B



G9 = 4-6 2-31 4-32

G11 = 64



G12 = CH2Ph (opt. substd.)
G19 = 193

Patent location: claim 1
Note: and pharmaceutically acceptable salts
Note: additional derivatization also claimed
Note: also incorporates broader disclosure
Stereochemistry: and individual diastereomers

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 15 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 140:423677 MARPAT Full-text
TITLE: Preparation of 3-(tetrahydropyranylamino)cyclopentanecarboxylic acid N-benzylamide derivatives and related compounds as modulators of chemokine receptor activity
INVENTOR(S): Butora, Gabor; Mills, Sander G.; Pasternak, Alexander; Shankaran, Kothandaraman; Yang, Lihu; Zhou, Changyou; Goble, Stephen D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041161	A2	20040521	WO 2003-US33972	20031024
WO 2004041161	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502174	A1	20040521	CA 2003-2502174	20031024
AU 2003286701	A1	20040607	AU 2003-286701	20031024
AU 2003286701	B2	20081218		
EP 1558243	A2	20050803	EP 2003-777911	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514003	T	20060427	JP 2004-550126	20031024

US 20060116421 A1 20060601 US 2005-533326 20050502
US 7390803 B2 20080624
PRIORITY APPLN. INFO.: US 2002-422451P 20021030
WO 2003-US33972 20031024

AB The title compds. (I) [wherein: X = O, NR20, S, SO, SO2, CR21R22, NSO2R20, NCOR20, NCO2R20, CR21CO2R20, CR21OCOR20, CO, OC(Me)2O (where R20 = H, C1-6 alkyl, benzyl, Ph, C3-6 cycloalkyl, etc.; R21, R22 = H, HO, C1-6 alkyl, C1-6 alkoxy, benzyl, Ph, C3-6 cycloalkyl, etc.); R1 = C1-6 alkyl, C1-6 alkoxy-C0-6 alkyl, C1-6 alkyl-S(O)0-2-C0-6-alkyl, N-(un)substituted C1-6 alkylaminosulfonyl-C0-6alkyl, -(C0-6 alkyl)(C3-7 cycloalkyl)(C0-6 alkyl), HO, CO2R20, heterocyclyl, cyano, NR20R26, NR26SO2R20, NR26COR21, OCOR20, Ph (where R26 = H, C1-6 alkyl, benzyl, Ph, etc.); R2, R4, R6 = H, C1-6 alkyl, CF3, CF3O, Cl, Br, Ph; R3 = H, HO, halo, C1-6 alkyl, C1-6 alkoxy, , NR20R21, NR20CO2R21, NR20CONR20OR21, NR20SO2NR20R21, NR20SO2R21, heterocyclyl, cyano, CONR20R21, CO2R20, NO2, SR20, SOR20, SO2R20, SO2NR20R21: R5 = C1-6 alkyl substituted with 1-6 F and optionally substituted with HO, C1-6 alkoxy or CO-C1-6 alkyl each substituted with 1-6 fluoro, C1-6 alkylthio, pyridyl, F, Cl, Br, Ph; R7 = H, C1-6 alkyl, CF3; R8, R9, R10 = H, (un)substituted C1-6 alkyl; or R7 and R8 or R8 and R9 may be joined together to form a ring; R11 = H, C1-6 alkyl, CF3; R27, R28 = oxo, H, Ph, (un)substituted C1-6 alkyl; R29, R30, R31 = H, Me, HO, CF3, MeO, CF3O; or R29 and R9 are connected by a C1-3alkyl bridge; m, n = 0-2; the dashed line = a single or a double bond] and pharmaceutically acceptable salts thereof and individual diastereomers thereof are prepared These compds. are useful as modulators of the chemokine receptor CCR-2 for (a) treating, ameliorating or controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease or (b) treating, ameliorating or controlling rheumatoid arthritis (no data). Thus, reductive amination of N-[3,5-bis(trifluoromethyl)benzyl]-3-oxo-1- isopropylcyclopentane-1-carboxamide with 4-aminotetrahydro-4H-pyran hydrochloride using triacetoxyborohydride in the presence of diisopropylethylamine in CH2Cl2 at room temperature overnight gave 46% N-[3,5-bis(trifluoromethyl)benzyl]-3-(tetrahydro-4H-pyran-4-ylamino)-oxo-1- isopropylcyclopentane-1-carboxamide (II).

MSTR 1



G9 = Pr-i
G27 = (0-2) 114

G29 = (0-2) 116

G31 = NH
G33 = C(O)
Patent location: claim 1
Note: and pharmaceutically acceptable salts
Note: additional ring formation also claimed
Stereochemistry: and diastereomers

L33 ANSWER 16 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 141:424568 MARPAT Full-text
TITLE: Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography
INVENTOR(S): Miyata, Takuya; Kawabata, Kouji; Kagawa, Takumi
PATENT ASSIGNEE(S): Tosoh Corporation, Japan
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479669	A1	20041124	EP 2004-11985	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2004346011	A	20041209	JP 2003-144793	20030522
US 20040235937	A1	20041125	US 2004-847289	20040518
US 7186750	B2	20070306		
US 20070131616	A1	20070614	US 2007-653373	20070116
US 7381742	B2	20080603		
US 20080230482	A1	20080925	US 2008-81753	20080421
PRIORITY APPLN. INFO.:			JP 2003-144793	20030522
			US 2004-847289	20040518
			US 2007-653373	20070116

AB An optically active maleimide derivative and its polymer are prepared Thus, the reaction of maleic anhydride with (1S,2S)-2-benzyloxycyclopentylamine in solvent in the presence of ZnCl2 gave N-((1S,2S)-2-benzyloxycyclopentyl)maleimide (91%), which was purified prior to polymerization

MSTR 1

G2 = 22 / 27 / 29 / cycloalkyl <containing 3-10 C> / 36



G4 = 24

G6 = (1-2) CH2
G7 = Ph (opt. substd. by (1-4) G5)
G8 = NH
Patent location: claim 1
Note: also incorporates claim 5

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 17 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 130:139656 MARPAT Full-text
TITLE: Preparation of Dolastatin 15 derivatives as antitumor agents
INVENTOR(S): Janssen, Bernd; Barlozzari, Teresa; Haupt, Andreas; Zierke, Thomas; Kling, Andreas
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany; BASF Bioresearch Corporation
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903879	A1	19990128	WO 1998-US13901	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6143721	A	20001107	US 1997-896394	19970718
CA 2296036	A1	19990128	CA 1998-2296036	19980707
CA 2296036	C	20070501		
AU 9884758	A	19990210	AU 1998-84758	19980707
AU 750120	B2	20020711		
EP 991658	A1	20000412	EP 1998-935531	19980707
EP 991658	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				

TR	200000132	T2	20000522	TR 2000-132	19980707
BR	9810911	A	20000801	BR 1998-10911	19980707
HU	2000004234	A2	20010528	HU 2000-4234	19980707
JP	2001515010	T	20010918	JP 2000-503101	19980707
NZ	502296	A	20020201	NZ 1998-502296	19980707
TR	200103545	T2	20020621	TR 2001-3545	19980707
RU	2195462	C2	20021227	RU 2000-103960	19980707
IL	133784	A	20050925	IL 1998-133784	19980707
AT	314387	T	20060115	AT 1998-935531	19980707
CN	1268636	C	20060809	CN 1998-807359	19980707
ES	2258819	T3	20060901	ES 1998-935531	19980707
PL	197884	B1	20080530	PL 1998-338144	19980707
SK	286581	B6	20090107	SK 1999-1879	19980707
ZA	9806358	A	20000117	ZA 1998-6358	19980717
IN	1998MA01605	A	20050304	IN 1998-MA1605	19980717
TW	533217	B	20030521	TW 1998-87111729	19980718
MX	2000000019	A	20010629	MX 2000-19	20000103
NO	2000000231	A	20000117	NO 2000-231	20000117
NO	326827	B1	20090223		
BG	104089	A	20001229	BG 2000-104089	20000117
BG	65212	B1	20070731		
US	6458765	B1	20021001	US 2000-618694	20000718
HK	1029125	A1	20070309	HK 2000-108461	20001228
US	20030153505	A1	20030814	US 2002-255118	20020925
US	7084110	B2	20060801		
US	20060270606	A1	20061130	US 2006-406512	20060418
JP	2009137967	A	20090625	JP 2008-315263	20081211
JP	2009137968	A	20090625	JP 2008-315269	20081211

PRIORITY APPLN. INFO.:

US 1997-896394	19970718
JP 2000-503101	19980707
WO 1998-US13901	19980707
US 2000-618694	20000718
US 2002-255118	20020925

AB Peptides A-B-D-E-F-(G)r-(K)s-L (I) [A = (un)substituted proline derivative or other (un)substituted α-amino acid; B = Val, Ile, allo-Ile, Nva, NHCR1bR2bCO (R1b = H, R2b = alkyl, alkenyl or R1b and R2b together are isopropylidene); D = N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkylisoleucyl, or other (un)substituted α-amino acid; E, F = (un)substituted aza-heterocyclylcarbonyl such as a prolyl residue or a 2- or 3-aminocyclopentanecarboxylic acid derivative; G, K = (un)substituted α-amino acid; L = (un)substituted amino, hydrazido, aminooxy, or oximato group; s and r = independently, 0 or 1], and acid salts thereof, were prepared The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of formula I in a pharmaceutically acceptable composition Thus, dolastatin derivative II was prepared by coupling H-Val-MeVal-Pro-Pro-NHCH2Ph.HCl (MeVal = N-methylvaline) with N-methyl-piperidine-2-carboxylic acid in DMF using diethylphosphoryl cyanide (DEPCN) and Et3N, and the diastereomeric mixture was separated by flash chromatog. In a cytotoxicity assay containing HT-29 colon carcinoma cells, dolastatin derivative II (D-piperidine isomer) had an IC50 value of 6.8 x 10-10 mol/L.

MSTR 1



G5 = 45-4 411-6



G6 = 359-5 361-46



G12 = cyclopropyl (opt. substd. by 1 or more F)
G42 = Ph (opt. substd. by 1 or more G37)
G43 = 339-45 342-411

Derivative: or salts
Patent location: claim 1
Note: also incorporates broader disclosure

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 18 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 130:139648 MARPAT Full-text
TITLE: Preparation of bicyclic metabotropic glutamate receptor ligands
INVENTOR(S): Kozikowski, Alan P.; Steensma, Darryl Hugh; Tueckmantel, Werner; Araldi, Gian Luca
PATENT ASSIGNEE(S): Georgetown University, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903822	A1	19990128	WO 1998-US14909	19980717

W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

CA 2296310	A1	19990128	CA 1998-2296310	19980717	
AU 9885754	A	19990210	AU 1998-85754	19980717	
AU 743899	B2	20020207			
EP 1000015	A1	20000517	EP 1998-936911	19980717	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
US 6204292	B1	20010320	US 1998-118042	19980717	
JP 2001515839	T	20010925	JP 2000-503053	19980717	
US 20010018429	A1	20010830	US 2001-769737	20010125	
US 6376532	B2	20020423			
US 20020165200	A1	20021107	US 2002-92388	20020306	
US 6610743	B2	20030826			
US 6825211	B1	20041130	US 2003-644645	20030820	
PRIORITY APPLN. INFO.:			US 1997-52972P	19970718	
			US 1997-64304P	19971105	
			US 1998-118042	19980717	
			WO 1998-US14909	19980717	
			US 2001-769737	20010125	
			US 2002-92388	20020306	

AB The present invention provides bicyclic metabotropic glutamate receptor ligands I [R1, R2, R3, R4, R7, R8, R9, and R10 = each independently H, CO2H, tetrazolyl, SO3H, PO3H2, B(OH)2, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halo-C1-6 alkyl, HO-C1-6 alkyl, C1-6 alkanoyloxy, C1-6 alkoxycarbonyl, CN, halo, CONRaRb, NRcRd, SRe, aryl, heteroaryl, aryl-C1-6 alkyl, diaryl-C1-6 alkyl, heteroaryl-C1-6 alkyl; , R5 = CO2H, tetrazolyl, C1-6 alkoxycarbonyl, SO3H, PO3H2, B(OH)2; R6 = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl, aryl, aryl-C1-6 alkyl, heteroaryl, heteroaryl-C1-6 alkyl, C1-6 alkoxycarbonyl, C1-6 alkanoyl; X = bond, O, S, SO, SO2, CRfRg, Se, PRx, NRx; Rx = H, C1-6 alkyl, C1-6 alkanoyl, aryl, aryl-C1-6 alkyl, , C1-6 alkoxycarbonyl, aryl-C1-6 alkoxycarbonyl; each Ra, Rb, Rc, Rd, Re, Rf, Rg = independently H, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkanoyl, aryl, heteroaryl, CH2Ph, CH2CH2Ph, etc.; NRcRd may form heterocyclic ring; RfRg = O, S], as well as compns. comprising such ligands, and methods for their use. Thus, acidic hydrolysis of allylserine derivative II, followed by N-protection, Swern oxidation and olefination with Me (triphenylphosphoranylidene)acetate gave 58% diene III (Cbz = CO2CH2Ph). Photolysis of III gave aminobicyclo[2.1.1]hexanedicarboxylates IV (R = Me, R11 = Cbz) as a mixture of all 4 stereoisomers, from which V (R = Me, R11 = Cbz) could be isolated in 32% yield. Hydrogenolysis of IV (R = Me, R1 = Cbz) to the corresponding free amines IV (R = Me, R11 = H) allowed the separation and isolation of the stereoisomers, and acidic hydrolysis gave title compds. IV and V (R = R11 = H). Formulations containing the title compds. are given, as is test data for interaction with metabotropic glutamate receptors.

MSTR 1



G1 = tetrazolyl / 20

G2 = 181

G9 = NH2
G11 = bond
G16 = (1-2) CH2
Derivative: or pharmaceutically acceptable salts or prodrugs
Patent location: claim 1
Note: substitution is restricted

MSTR 2



G1 = tetrazolyl / 20

G2 = 181

G9 = NH2
G11 = bond
G16 = (1-2) CH2
Derivative: or pharmaceutically acceptable salts

Patent location: claim 10
Note: substitution is restricted

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 19 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 130:95843 MARPAT Full-text
TITLE: Preparation of cyclopentylcarbonylamino acid as inhibitors of α4β1 mediated cell adhesion
INVENTOR(S): Lobl, Thomas J.; Rishton, Gil; Teegarden, Bradley; Polinsky, Alex; Yamagishi, Masafumi; Tanis, Steven P.; Fisher, Jed F.; Thomas, Edward W.; Chrusciel, Robert A.
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858902	A1	19981230	WO 1998-US13064	19980623
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9881633	A	19990104	AU 1998-81633	19980623
EP 991619	A1	20000412	EP 1998-931521	19980623
EP 991619	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517246	T	20011002	JP 1999-504997	19980623
US 6482849	B1	20021119	US 1998-102584	19980623
AT 249421	T	20030915	AT 1998-931521	19980623
ES 2206953	T3	20040516	ES 1998-931521	19980623
US 20030130349	A1	20030710	US 2002-193137	20020712
US 6596752	B1	20030722		
PRIORITY APPLN. INFO.:			US 1997-50515P	19970623
			US 1998-102584	19980623
			WO 1998-US13064	19980623

AB Title compds. [I; n = 0, 1; R1 = H, CH3; R2 = CN, CO2H, CONH2, CONHOCH2Ph, NHCOOCH2Ph, etc.; R3 = H, CH3; X = CH, CO; R4 = H, alkyl; R5 = CO2H, CONH2, COOR, etc.; R = alkyl; R6 = aryl, heteroaryl, arylcarbonyl, aarylcarbonylaminoalkyl, etc.], a pharmaceutically acceptable salt, a stereoisomer thereof are prepared as inhibitors of α4β1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing α4β1 adhesion mediated conditions in human such as inflammatory diseases. Thus, (1S-cis)- N-[(3-carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-O-(phenylmethyl)- L- tyrosine was prepared and assayed for inhibition of β1-mediated cell adhesion in vitro.

MSTR 1



G2 = 50



G9 = Me
G10 = C(O)
G11 = NH
G13 = (0-1) CH2
G18 = 233

G31 = phenylene (opt. substd.)
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: substitution is restricted

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 20 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 129:81958 MARPAT Full-text
TITLE: Preparation of amino acid piperidine, pyrrolidine, and hexahydro-1H-azepine derivatives for promoting release of growth hormone
INVENTOR(S): Chen, Meng H.; Lu, Zhijian; Nargund, Ravi; Patchett, Arthur A.; Tata, James R.; Wu, Mu Tsu; Yang, Lihu
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825897	A1	19980618	WO 1997-US22725	19971210

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US,

UZ, VN, YU
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9855998	A	19980703	AU 1998-55998	19971210
US 5965565	A	19991012	US 1997-988816	19971211
PRIORITY APPLN. INFO.:			US 1996-32649P	19961212
			GB 1997-2954	19970213
			WO 1997-US22725	19971210

AB Compds. BCOCR1R1aNR2aCO(CR4aR4b)xE(CR4aR4b)yNR4R5 [B = substituted piperidinyl, pyrrolidinyl, and hexahydro-1H-azepinyl; R1 = alkyl, aryl, arylalkyl, heteroaryl, etc.; R1a, R2a = H, alkyl; R4a, R4b = H, alkyl, trifluoromethyl, Ph, substituted alkyl; E = cyclohexanediyl, piperidinediyl, bicyclo[2.2.2]octane-1,4-diyl, cyclopentanediyl, pyrrolidinediyl; R4, R5 = H, (un)substituted alkyl; x, y = 0, 1, 2, 3] were prepared for promoting growth hormone in humans and animals. Thus, Boc-D-tryptophan underwent amidation reactions to afford I.HCl.

MSTR 1



G1 = 19-9 18-2



G5 = bond
G6 = Ph (opt. substd. by (1-2) G47)
G19 = 86

G23 = 475-2 482-4



G24 = 538

538 G67

G60 = (0-3) CH2 (opt. substd.)
G65 = bond
G67 = Me
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Note: additional ring formation also claimed
Stereochemistry: and individual diastereomers

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 21 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 129:15967 MARPAT Full-text
TITLE: Preparation of arylcycloalkanes as tachykinin receptor antagonists.
INVENTOR(S): Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Finke, Paul; Hale, Jeffrey; Holson, Edward; Kopka, Ihor; Maccoss, Malcolm; Meurer, Laura; Mills, Sander G.; Robichaud, Albert
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 109 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5750549	A	19980512	US 1996-730277	19961015

PRIORITY APPLN. INFO.: US 1996-730277 19961015

AB Title compds. [I; R3 = H, alkoxy, phenylalkoxy, Ph, cyano, halo, amino, (substituted) alkyl, null; R6-R8 = H, alkoxy, halo, (substituted) alkyl, OH, cyano, CF3, NO2, heterocyclyl, etc.; R11-R13 = H, (substituted) alkyl, halo, cyano, CF3, NO2, OH, alkoxy, etc.; A = Ph, benzofuranyl, benzothiophenyl, benzothiazoyl, indolyl, imidazolyl, oxadiazolyl, pyridyl, pyrimidyl, quinolinyl, thiazolyl, thienyl, thiophenyl, dihydrobenzofuranyl; Q = H, alkyl; W = O, NH, alkylimino, NHCO, alkyliminocarbonyl; X = H, alkyl; Y = bond, (substituted) alkyl; Z = NR15, CONR15, SO2NR15, SO2, CO2R15, CH2OR15, null; R15 = H, (substituted) alkyl; n = 1-3; with provisos], were prepared Thus, Me 3(SR)-hydroxy-2(RS)-phenylcyclopentane-1(RS)-carboxylate (preparation given) was treated with 3,5-bis(trifluoromethyl)benzyl bromide and NaH in DMF to give Me 3(SR)-[3,5-bis(trifluoromethyl)phenylmethoxy]-2(RS)- phenylcyclopentane-1(RS)-carboxylate. I showed intrinsic tachykinin receptor antagonist activity in the range 0.05-10 μM.

MSTR 1

G3 = 95-2 96-8

G4 = NH
G6 = alkyl <containing 1-6 C>
G9 = 107

G11 = 157

G24 = 167

G26 = Ph
G32 = (0-2) CH2
G37 = 241

G38 = 251

G42 = carbon chain <containing 1-6 C, saturated>
(opt. substd.)
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: additional substitution also claimed
Note: substitution is restricted

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 22 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 127:17433 MARPAT Full-text
TITLE: Cyclopentyl tachykinin receptor antagonists
INVENTOR(S): Finke, Paul E.; Maccoss, Malcom; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffery; Holson, Edward; Kopka, Ihor; Robichaud, Albert
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Finke, Paul E.; Maccoss, Malcolm; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffrey; et al.
SOURCE: PCT Int. Appl., 343 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714671	A1	19970424	WO 1996-US16489	19961015
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2234913	A1	19970424	CA 1996-2234913	19961015
AU 9710497	A	19970507	AU 1997-10497	19961015
AU 722883	B2	20000810		
EP 858444	A1	19980819	EP 1996-941315	19961015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002534955	T	20021015	JP 1997-515929	19961015
PRIORITY APPLN. INFO.:			US 1995-5558P	19951018
			GB 1996-5160	19960312
			WO 1996-US16489	19961015

AB The invention is directed to certain novel compds. I and their pharmaceutically acceptable salts [wherein R3 = H, OH, alkoxy, Ph, cyano, halo, (un)substituted NH2, heterocyclyl, etc.; R6, R7, R8 = H, alkoxy, halo, (un)substituted alkyl, OH, cyano, CF3, etc.; R11, R12, R13 = H, (un)substituted alkyl, halo, cyano, CF3, etc.; A = benzene or various heterocycles; Q = H, alkyl; W = O, NH, alkylimino, NHCO, alkyliminocarbonyl; X = H, alkyl; Y = bond, (un)substituted alkyl; Z = (un)substituted NH, CONH, NHCO, SO2NH, NHSO2, SO2, CO2H, etc.; n = 1, 2, 3]. The invention is also concerned with pharmaceutical formulations comprising I as active ingredients, and use of I and their formulations in the treatment of certain disorders. I are tachykinin receptor antagonists (no data) and are useful in the treatment of inflammatory diseases, pain, migraine, asthma, and emesis. For instance, reductive alkylation of the appropriate amine with 2-methoxy-5-(1-

tetrazolyl)benzaldehyde, by treatment with AcOH and 3A sieves in MeOH followed by NaBH3CN, gave title compound II.

MSTR 1

G3 = 95-2 96-8

G4 = NH
G6 = alkyl <containing 1-6 C>
G9 = 107

G11 = 157

G14 = carbon chain <containing 1-6 C, saturated>
(opt. substd.)
G24 = 167

G26 = Ph
G32 = (0-2) CH2
G37 = 241

G38 = 251

Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: additional substitution also claimed
Note: substitution is restricted

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 23 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 127:51005 MARPAT Full-text
TITLE: Preparation of N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives as anxiolytics and cholecystokinin activity-modifying agents
INVENTOR(S): Horwell, David C.; Pritchard, Martyn C.; Roberts, Edward; Richardson, Reginald S.; Aranda, Julian
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 108 pp., Cont.-in-part of U.S. Ser. No. 958,196, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5631281	A	19970520	US 1994-235814	19940428
AU 9059628	A	19910117	AU 1990-59628	19900628
AU 644088	B2	19931202		
ZA 9005057	A	19920226	ZA 1990-5057	19900628
EP 479910	A1	19920415	EP 1990-911185	19900628
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04506079	T	19921022	JP 1990-510126	19900628
JP 2972331	B2	19991108		
CA 2060652	C	20010821	CA 1990-2060652	19900628
CA 2344707	C	20020730	CA 1990-2344707	19900628
US 5278316	A	19940111	US 1990-629809	19901219
FI 106197	B1	20001215	FI 1991-6060	19911220
NO 9105122	A	19920227	NO 1991-5122	19911227
NO 301831	B1	19971215		
US 5580896	A	19961203	US 1995-447142	19950522
US 5622983	A	19970422	US 1995-447141	19950522
PRIORITY APPLN. INFO.:			US 1989-374327	19890629
			US 1989-422486	19891016
			US 1990-580811	19900605
			US 1990-545222	19900628
			US 1990-629809	19901219
			US 1992-958196	19921007
			US 1990-530811	19900605

NZ 1990-234264 19900627
CA 1990-2060652 19900628
WO 1990-US3553 19900628
US 1994-235814 19940428

AB Novel unnatural dipeptoids I [R1 = C3-12 (poly)cycloalkyl containing 0-4 substituents each (un)branched C1-6 alkyl, halo, CN, OR, SR, CO2R, CF3, NR5R6, (CH2)nOR5; R = (un)branched C1-6 alkyl, R5, R6 = H, C1-6 alkyl, n = 0-6; A = (CH2)nCO, SO2, S(O), NHCO, (CH2)nO2C, SCO, O(CH2)nCO, CH:CHCO; R2 = (un)branched C1-6 alkyl, CH:CH2, C.tplbond.CH, CH2CH:CH2, CH2C.tplbond.CH, (CH2)nAr, (CH2)nOR, (CH2)nOAr, (CH2)nCO2R, (CH2)nNR5R6; R3, R4 = independently H, R2, (CH2)q-B-D; q = 0-3; B = bond, O2C(CH2)n, O(CH2)n, SO2NH(CH2)n, NHCO(CH2)n, CONH(CH2)n, NHCOCH:CH, CO2(CH2)n, CO(CH2)n, S(CH2)n, S(O)(CH2)n, SO2(CH2)n, CONHCR7:CR8, NHCOCR7:CR8, CONHCHR7CHR8, NHCOCHR7CHR8, CR7:CR8, CHR7CHR8; R7, R8 = independently H, R2; R7R8 = (CH2)m, m = 1-5; D = CO2R, CH2OR, CHR2OR, CH2SR, CHR2SR, CONR5R6, CN, NR5R6, OH, PhSO2NHCO, CF3CONHCO, CF3SO2NHCO, H2NSO2, H, acid replacement group such as tetrazole; R9 = H, (un)branched C1-6 alkyl, (CH2)nCO2R, (CH2)nOAr, (CH2)nAr, (CH2)nNR5R6; R10 = OH, NH2, Me, Cl; R11 = CN, CO2H, CF3; Ar = 2- or 3-thienyl, 2- or 3-furanyl, 2-, 3- or 4-pyridinyl, (un)substituted Ph containing H, halo, Me, OMe, CF3, NO2, OH, NH2, OCF3, NHCOCH2CH2CO2H, or CH2CH2CO2H groups; R12, R13 = H, or taken with R3 and R4 form a double bond] are disclosed. I are α-substituted Trp-Phe derivs. useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics. Further, compds. I are antianxiety agents, antiulcer agents, antidepressant agents, and are agents useful for preventing the withdrawal response produced by chronic treatment or use followed by chronic treatment followed by withdrawal from nicotine, diazepam, alc., cocaine, caffeine, or opioids. Also disclosed are pharmaceutical compns. and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation An addnl. feature of the invention is the use of the subject compds. to prepare pharmaceutical and diagnostic compns. Thus, methyltryptophan derivative II, prepared from tert-butoxycarbonyl-L-phenylalaninol, 2-adamantyloxycarbonyl-α-methyl-D-tryptophan, and monomethyl fumarate, displayed Ki = 0.00008 μM in a central cholecystokinin binding assay.

MSTR 1



G1 = 123



G5 = C(O)
G7 = Ph (opt. substd. by 1 or more G31)
G22 = CF3 / NH2
G23 = (1-3) CH2 (opt. substd. by G21)
Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: also incorporates broader disclosure
Note: substitution is restricted

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 24 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 123:9461 MARPAT Full-text
TITLE: Preparation of piperazinylcamphor-derivative oxytocin antagonists
INVENTOR(S): Bock, Mark G.; Hobbs, Doug W.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502587	A1	19950126	WO 1994-US7769	19940711
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2166974	A1	19950126	CA 1994-2166974	19940711
AU 9473292	A	19950213	AU 1994-73292	19940711
AU 675730	B2	19970213		
EP 708765	A1	19960501	EP 1994-923424	19940711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500133	T	19970107	JP 1994-504653	19940711
US 5686454	A	19971111	US 1996-578640	19960116
PRIORITY APPLN. INFO.:			US 1993-93502	19930716
			WO 1994-US7769	19940711

AB The title compds. [I; a = single or double bond; R1, R2 = H, (un)substituted alkyl, halogen, alkoxy; R5, R6 = H, alkyl, phenylalkyl, oxo; R7, R8 = H, alkyl; R9, R10 = H, OH, halogen, oximido, Me, CO2H, etc.; R11 = H, oxo, (un)substituted aminocarbonyl, etc.; W = C, O; X = CH, N; Y = CO, sulfonyl, CONH; Z = (un)substituted alkyl; m, n = 0, 1; R9R10 = cyclic epoxide substituent], useful as oxytocin antagonists in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to a cesarean delivery, etc., are prepared Thus, piperazine II was prepared and demonstrated 54% inhibition at 1000 nM of the binding of tritiated oxytocin to rat uterus-derived oxytocin receptors.

MSTR 1A

G7 = 144-3 143-43



G10 = Me / 80

G14 = 265

G15 = 272

G22 = alkyl (opt. substd. by 1 or more G23)
G23 = indolyl
Patent location: claim 1
Note: substitution is restricted

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 25 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 121:280369 MARPAT Full-text
TITLE: Bicyclooctane- and bicycloheptane-derivative gastrin and/or cholecystokinin receptor antagonists
INVENTOR(S): Kalindjian, Sarkis Barret; Low, Caroline Minli Rachel; Pether, Michael John; Davies, Jonathan Michael Richar; Dunstone, David John; McDonald, Iain Mair
PATENT ASSIGNEE(S): James Black Foundation Ltd., UK
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9400421	A1	19940106	WO 1993-GB1301	19930618
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
GB 2268739	A	19940119	GB 1992-13094	19920619
AU 9343489	A	19940124	AU 1993-43489	19930618
EP 655053	A1	19950531	EP 1993-913402	19930618
EP 655053	B1	19970903		
R: DE, ES, FR, GB, IT				
US 5674905	A	19971007	US 1994-351320	19941219
PRIORITY APPLN. INFO.:			GB 1992-13094	19920619
			GB 1992-26549	19921221
			WO 1993-GB1301	19930618

AB The title compds. [I; A = (un)substituted fused naphtho, etc.; B = fused benzo, etc.; R1 = H, Me, halogen; (un)substituted CO2H, tetrazolyl, etc.; R2 = R1, (un)substituted carbonyl derivative; R3, R4 = H, halogen, NH2, NO2, CN, sulfamoyl, C1-3 alkyl, C1-3 alkoxy, (un)substituted CO2H, tetrazolyl; W = CO, sulfonyl, sulfinyl; X = W, COCH2; Y = R9O, R9NR10; R9 = H, C1-15 hydrocarbyl; R10 = H, C1-3 alkyl, CO2Me, etc.; Z = OR11, (un)substituted QNH, etc.; R11 = H, C1-5 alkyl, (un)substituted Ph or PhCH2; Q = H, C1-5 hydrocarbyl, etc.], which are gastrin and/or cholecystokinin receptor antagonists, are prepared Thus, naphthalene was subjected to cycloaddn. with maleic anhydride, and the endo isomer intermediate amidated with 1-adamantylmethylamine, producing endo-(±)-cis-8-(1- adamantylmethylaminecarbonyl)-5,6-benzobicyclo[2.2.2]oct-2-ene-7- carboxylic acid (II). II demonstrated gastrin receptor pKB 5.9 and the cholecystokinin receptor pKi 5.6.

MSTR 1



G1 = 32

G11 = C(O)
G12 = 50

5 G13—G17

G13 = NH
G17 = 160

1 G51—G49

G46 = tetrazolyl
G48 = NH2
G49 = Ph
G51 = (1-3) CH2
Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Note: additional ring formation possible
Note: substitution is restricted

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 26 OF 26 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 119:226417 MARPAT Full-text
TITLE: Preparation of condensed pyrimidinylacyl amino acids as neoplasm inhibitors
INVENTOR(S): Akimoto, Hiroshi; Ootsu, Koichiro; Itoh, Fumio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 530537	A1	19930310	EP 1992-113523	19920807
EP 530537	B1	19970108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5403843	A	19950404	US 1992-926170	19920807
AT 147386	T	19970115	AT 1992-113523	19920807
CA 2075787	A1	19930213	CA 1992-2075787	19920811
JP 06049069	A	19940222	JP 1992-214142	19920811
JP 3376479	B2	20030210		

PRIORITY APPLN. INFO.: JP 1991-202042 19910812
JP 1992-71513 19920327
JP 1992-145851 19920605
OTHER SOURCE(S): CASREACT 119:226417
AB Title compds. [I; ring A = (substituted) (hydrogenated) 5-membered ring; B = (substituted) divalent 5- or 6-membered homo- or heterocyclic group; X = amino, OH, SH; Y = H, halo, C-, N-, O-, or S-bonded group; Z = (substituted) (heteroatom-containing) divalent group having ≤5 atoms; W = NRCO; R = H, (substituted) alkyl; R1 = (substituted) cyclic or chain-like group; or RR1 =

atoms to form a 3-13 membered ring CO2R2 = optionally esterified carboxyl group; p = 1-4; with provisos], were prepared Thus, Nα-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-Nδ-phthaloyl-L-ornithine Me ester [prepared by condensation of the corresponding benzoic acid with Nδ-phthaloyl-L-ornithine Me ester.HCl using di-Et cyanophosphate and Et3N in DMF] was saponified to give Nα-[4-[2-(2,4-diamino-7H- pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-Nδ-hemiphthaloyl-L- ornithine. This inhibited proliferation of A549 cells with IC50 = 0.0012 μg/mL.

MSTR 1A



G1 = 25-1 23-2 25-10

G5 = cycloalkyl <containing 3-6 C> / NO2
G6 = 58

G8 = 240-10 237-12

G20 = 75-9 77-11 / 263-9 264-11 / 266-9 265-11

G22 = carbon chain <containing 1-4 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by (1-2) G19) / 255

G23 = 106

G44 = carbon chain <containing up to 5 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
Derivative: or salts
Patent location: claim 1
Note: substitution is restricted

MSTR 1B



G1 = 25-2 23-1 25-10

G5 = cycloalkyl <containing 3-6 C> / NO2
G6 = 58

G8 = 240-10 237-12

G20 = 75-9 77-11 / 263-9 264-11 / 266-9 265-11

G22 = carbon chain <containing 1-4 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by (1-2) G19) / 255

G23 = 106

G44 = carbon chain <containing up to 5 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
Derivative: or salts
Patent location: claim 1
Note: substitution is restricted

MSTR 2A



G1 = 25-1 23-2 25-10

G5 = cycloalkyl <containing 3-6 C> / NO2
G6 = 58

G8 = 240-10 237-12

G20 = 75-9 77-11 / 263-9 264-11 / 266-9 265-11



G22 = carbon chain <containing 1-4 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by (1-2) G19) / 255

G23 = 106

G44 = carbon chain <containing up to 5 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
Derivative: or salt reactive derivatives
Patent location: claim 72

MSTR 2B



G1 = 25-2 23-1 25-10

G5 = cycloalkyl <containing 3-6 C> / NO2
G6 = 58

G8 = 240-10 237-12

G20 = 75-9 77-11 / 263-9 264-11 / 266-9 265-11



G22 = carbon chain <containing 1-4 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by (1-2) G19) / 255

G23 = 106

G44 = carbon chain <containing up to 5 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
Derivative: or salt reactive derivatives
Patent location: claim 72

Search History

```
L1              STRUCTURE UPLOADED
L2            7 SEA SSS SAM L1

     FILE 'HCAPLUS' ENTERED AT 14:46:33 ON 05 NOV 2009
L3            1 SEA SPE=ON  ABB=ON  PLU=ON  US2006-585232/APPS

     FILE 'REGISTRY' ENTERED AT 14:46:54 ON 05 NOV 2009
L4          294 SEA SPE=ON  ABB=ON  PLU=ON  (100-06-1/BI OR 100-10-7/BI OR
                10075-38-4/BI OR 1013-88-3/BI OR 1029820-47-0/BI OR 1029820-58-
                3/BI OR 1029822-79-4/BI OR 104-86-9/BI OR 104-88-1/BI OR
                104508-22-7/BI OR 105-45-3/BI OR 107-89-1/BI OR 107622-80-0/BI
                OR 110238-91-0/BI OR 1121-60-4/BI OR 1122-91-4/BI OR 1131-62-0/
                BI OR 114790-43-1/BI OR 115491-56-0/BI OR 117706-95-3/BI OR
                120-14-9/BI OR 120-57-0/BI OR 1203-68-5/BI OR 1204-60-0/BI OR
                123-11-5/BI OR 123-42-2/BI OR 124-13-0/BI OR 124432-69-5/BI OR
                129904-48-9/BI OR 130931-83-8/BI OR 134003-02-4/BI OR 135-02-4/
                BI OR 13865-20-8/BI OR 140-67-0/BI OR 141-46-8/BI OR 14774-37-9
                /BI OR 1489-69-6/BI OR 15206-55-0/BI OR 1522-46-9/BI OR
                153209-97-3/BI OR 1571-08-0/BI OR 1694-92-4/BI OR 17413-10-4/BI
                 OR 180323-49-3/BI OR 199678-28-9/BI OR 199678-32-5/BI OR
                200002-41-1/BI OR 20781-20-8/BI OR 20818-81-9/BI OR 21244-34-8/
                BI OR 2134-29-4/BI OR 2338-75-2/BI OR 2393-23-9/BI OR 252006-17
                -0/BI OR 2620-50-0/BI OR 284027-34-5/BI OR 3240-35-5/BI OR
                32811-75-9/BI OR 331-64-6/BI OR 33252-63-0/BI OR 3393-64-4/BI
                OR 34036-07-2/BI OR 34328-46-6/BI OR 3446-89-7/BI OR 351-54-2/B
                I OR 38923-57-8/BI OR 39151-19-4/BI OR 39750-93-1/BI OR
                400770-74-3/BI OR 401-95-6/BI OR 4088-84-0/BI OR 42365-62-8/BI
                OR 42726-73-8/BI OR 446-52-6/BI OR 456-48-4/BI OR 459-57-4/BI
                OR 460-40-2/BI OR 500-22-1/BI OR 50675-18-8/BI OR 513-86-0/BI
                OR 52178-50-4/BI OR 529-34-0/BI OR 53266-94-7/BI OR 5398-77-6/B
                I OR 541-50-4/BI OR 5445-17-0/BI OR 552-89-6/BI OR 5703-26-4/BI
                 OR 587-04-2/BI OR 590-90-9/BI OR 591-31-1/BI OR 597-31-9/BI
                OR 600-22-6/BI OR 609-12-1/BI OR 609-14-3/BI OR 60992-98-5/BI
                OR 613-45-6/BI OR 615-83-8/BI OR 624734-22-1/BI OR 624734-23-2/
                BI OR 624734-24-3/BI OR 624734-25-4/BI OR 624734-26-5/BI OR
                624734-27-6/BI OR 624734-28-7/BI OR 624734-29-8/BI OR 624734-30
                -1/BI OR 624734-33-4/BI OR 624734
L5          545 SEA SSS FUL L1
L6           63 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND L4
L7              STRUCTURE UPLOADED
L8           31 SEA SUB=L5 SSS SAM L7
L9          462 SEA SUB=L5 SSS FUL L7
L10          63 SEA SPE=ON  ABB=ON  PLU=ON  L9 AND L4

     FILE 'HCAPLUS' ENTERED AT 14:51:41 ON 05 NOV 2009
L11           7 SEA SPE=ON  ABB=ON  PLU=ON  L9
L12          30 SEA SPE=ON  ABB=ON  PLU=ON  GOBLE S?/AU
L13       18995 SEA SPE=ON  ABB=ON  PLU=ON  YANG L?/AU
L14        7601 SEA SPE=ON  ABB=ON  PLU=ON  ZHOU C?/AU
L15          22 SEA SPE=ON  ABB=ON  PLU=ON  KOTHANDARAMAN S?/AU
L16          18 SEA SPE=ON  ABB=ON  PLU=ON  GUIADEEN D?/AU
L17          53 SEA SPE=ON  ABB=ON  PLU=ON  BUTORA G?/AU
L18           2 SEA SPE=ON  ABB=ON  PLU=ON  PASTEMAK A?/AU
L19         794 SEA SPE=ON  ABB=ON  PLU=ON  MILLS S?/AU
L20       27313 SEA SPE=ON  ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR L15 OR L16
```

```
                OR L17 OR L18 OR L19)
L21           6 SEA SPE=ON  ABB=ON  PLU=ON  L20 AND L11

     FILE 'WPIX' ENTERED AT 14:56:43 ON 05 NOV 2009
L22          18 SEA SSS SAM L7
L23         131 SEA SSS FUL L7
L24           3 SEA SPE=ON  ABB=ON  PLU=ON  L23/DCR
L25           3 SEA SPE=ON  ABB=ON  PLU=ON  L20 AND L24

     FILE 'BEILSTEIN' ENTERED AT 14:57:40 ON 05 NOV 2009
L26           0 SEA SSS SAM L7
L27           0 SEA SSS FUL L7

     FILE 'MARPAT' ENTERED AT 14:57:58 ON 05 NOV 2009
L28           0 SEA SSS SAM L7
L29          25 SEA SSS FUL L7

     FILE 'HCAPLUS, WPIX' ENTERED AT 15:13:39 ON 05 NOV 2009
L30           6 DUP REM L21 L25 (3 DUPLICATES REMOVED)

     FILE 'HCAPLUS' ENTERED AT 15:14:18 ON 05 NOV 2009
L31           1 SEA SPE=ON  ABB=ON  PLU=ON  L11 NOT L21

     FILE 'WPIX' ENTERED AT 15:14:35 ON 05 NOV 2009
L32           0 SEA SPE=ON  ABB=ON  PLU=ON  L24 NOT L25

     FILE 'HCAPLUS, MARPAT' ENTERED AT 15:15:06 ON 05 NOV 2009
L33          26 DUP REM L31 L32 L29 (0 DUPLICATES REMOVED)
```